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JUDGING GENES: IMPLICATIONS OF THE SECOND
GENERATION OF GENETIC TESTS IN
THE COURTROOM
DIANE E. HOFFMANN*  & KAREN H. ROTHENBERG**
The use of DNA tests for identification has revolutionized court pro-
ceedings in criminal and paternity cases.  Now, requests by litigants
to admit or compel a second generation of genetic tests—tests to con-
firm or predict genetic diseases and conditions—threaten to affect
judicial decisionmaking in many more contexts.  Unlike DNA tests
for identification, these second generation tests may provide highly
personal health and behavioral information about individuals and
their relatives and will pose new challenges for trial court judges.
This Article reports on an original empirical study of how judges
analyze these requests and uses the study’s results to inform the con-
struction of a multi-factorial decision matrix to assist judges evalu-
ate the appropriate role of this information in legal proceedings.
Through this analytical framework, the Article illuminates doctrinal
and theoretical tensions in existing criminal, evidence, constitu-
tional, and tort law that are likely to surface when efforts are made to
apply current law in these areas to cases involving the use of health-
related genetic tests.  In addition, the Article examines the broader
implications of the wide-scale use of these tests in court proceedings
and argues that appellate judges and policymakers, who establish
procedural rules governing litigation, will need to consider the collat-
eral consequences of such use.  Moreover, changes in existing doc-
trines and rules may be necessary to accommodate challenges to
underlying legal theories and societal values, such as privacy and
responsibility, generated by the use of these tests in the courtroom.
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I. INTRODUCTION
Assume you are a judge presiding over the following two cases:
Case 1.  In a non-capital sentencing proceeding of a twenty-eight-year-old
man convicted of a violent homicide, the prosecutor requests that you compel the
defendant to have a genetic test for a gene mutation that predisposes an indi-
vidual to exhibit bouts of extreme rage.  Between fifty and sixty percent of indi-
viduals with this mutation exhibit these behavioral abnormalities before the age
at which the defendant committed the crime.  With this test result the prosecutor
wishes to show that the defendant has a proclivity toward violence (“future
dangerousness”).  The defendant objects to being compelled to have the test.
Case 2.  In the damages phase of a products liability case, the defendant
requests that you compel the twenty-one-year-old plaintiff to have a genetic test
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for Neurofibromatosis type II (NF-2), as his father died of the disease at the age
of forty.  NF-2 is a rare, inherited disorder characterized by the development of
benign tumors on both auditory nerves and by the development of malignant
central nervous system tumors.  The disease is unrelated to the injury caused by
the defendant’s product.  Virtually everyone who has the mutation develops the
disease; however, the severity of symptoms differs from person to person, and the
gene is not predictive of such disparities.  An expert testifies that the average age
of onset of NF-2 is between eighteen and twenty-four and that the average age of
death of those with the disease is thirty-six.  At present, the plaintiff has no
symptoms of the disease.
Would you compel the test in either case?
Soon, judges across the country may face questions similar to the
ones posed by these two hypothetical scenarios.  Genetic tests for over
1,000 diseases are currently available in clinical settings, and tests for
approximately 300 more diseases are being used in research contexts.1
The mapping of the human genome, completed in 2003,2 has gener-
ated a host of new and perplexing questions about the meaning and
appropriate use of health-related genetic tests.
At its core, the purpose of the Human Genome Project (HGP)
was to improve our understanding of health and genetic disease and
to develop diagnostic tests, therapies, and preventive measures to im-
prove the quality of life for individuals who would otherwise be debili-
tated by such diseases.3  Early on in the genesis of the HGP, however,
it was clear that information gleaned from genetic research could also
1. GeneTests, http://www.genetests.org/ (last visited May 19, 2007).  As of May 19,
2007, tests for 1,101 diseases were available for use in clinical settings and an additional 291
tests for research purposes. Id.
2. National Human Genome Research Institute, All About The Human Genome Pro-
ject (HGP), http://www.genome.gov/10001772 (last visited May 19, 2007).
3. National Human Genome Research Institute, An Overview of the Human Genome
Project, http://www.genome.gov/12011238 (last visited May 19, 2007); see also National
Human Genome Research Institute, The Human Genome Project Completion: Frequently
Asked Questions, http://www.genome.gov/11006943 (last visited May 19, 2007) (project-
ing that “genome-based research will eventually enable medical science to develop highly
effective diagnostic tools, to better understand the health needs of people based on their
individual genetic make-ups, and to design new and highly effective treatments for dis-
ease”).  The Institute further notes:
Individualized analysis based on each person’s genome will lead to a very
powerful form of preventive medicine.  We’ll be able to learn about risks of future
illness based on DNA analysis.  Physicians, nurses, genetic counselors and other
health-care professionals will be able to work with individuals to focus efforts on
the things that are most likely to maintain health for a particular individual.  That
might mean diet or lifestyle changes, or it might mean medical surveillance.  But
there will be a personalized aspect to what we do to keep ourselves healthy. Then,
through our understanding at the molecular level of how things like diabetes or
heart disease or schizophrenia come about, we should see a whole new genera-
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be employed for non-health-related purposes.4  In response to con-
cerns about ethical issues stemming from the Project, in 1990 the Na-
tional Human Genome Research Institute established its Ethical,
Legal and Social Implications (ELSI) Research Program.5  One of the
goals of the ELSI program was to consider the non-clinical uses of new
genetic information.6
Policymakers, legal academics, and the ELSI program have fo-
cused on the potential use of health-related genetic test results for
employment and insurance discrimination and argued for legislation
to prevent such improper use.7  Utilizing genetic tests to determine
the health status or predisposition to disease of courtroom litigants
has received relatively less attention.  This lack of attention contrasts
sharply with the legal system’s enthusiastic embrace of DNA tests for
purposes of identifying, or excluding from consideration, the perpe-
trator of a crime or the father of a child.8  In just twenty years the use
tion of interventions, many of which will be drugs that are much more effective
and precise than those available today.
Id.
4. See Francis S. Collins et al., A Vision for the Future of Genomics Research, 422 NATURE
835, 843 (2003) (explaining that “genomic information is not limited to the arenas of
biology and of health”: the range of additional users could likely include “the life, disability
and long-term care insurance industries, the legal system, the military, educational institu-
tions and adoption agencies”).
5. National Human Genome Research Institute, The Planning and Evaluation History
of the Ethical, Legal and Social Implications (ELSI) Research Program, http://gen-
ome.gov/10001754 (last visited May 19, 2007).
6. National Human Genome Research Institute, The Ethical, Legal and Social Impli-
cations (ELSI) Research Program, http://www.genome.gov/10001618 (last visited May 19,
2007).
7. See, e.g., Kathy L. Hudson et al., Genetic Discrimination and Health Insurance: An Urgent
Need for Reform, 270 SCI. 391, 391, 393 (1995) (noting that health insurance providers could
use genetic information to discriminate against individuals, and listing recommendations
for lawmakers to avoid such discrimination); Karen Rothenberg et al., Genetic Information
and the Workplace: Legislative Approaches and Policy Challenges, 275 SCI. 1755, 1755–57 (1997)
(warning of the societal risks of allowing employers to use genetic information to influence
employment decisions and describing federal and state legislative initiatives aimed at ad-
dressing genetic discrimination in the workplace); Karen H. Rothenberg & Sharon F.
Terry, Before It’s Too Late—Addressing Fear of Genetic Information, 297 SCI. 196, 197 (2002)
(arguing for a comprehensive federal statute to reduce possible abuse of genetic informa-
tion by employers and standardize the current patchwork of state laws).  Numerous state
legislatures have made efforts, with varying degrees of success, to pass legislation address-
ing this issue.  Recently, after over a decade of proposals, the U.S. House of Representa-
tives passed the Genetic Information Nondiscrimination Act of 2007 (GINA).
8. See Warren Richey, DNA Tests Gain Ground as Legal Defense, CHRISTIAN SCI. MONITOR,
Jan. 31, 2006, at 3 (stating that using DNA tests to exonerate wrongly convicted individuals
“is part of an evolution taking place across the country in which prosecutors and lawmakers
who were once suspicious of the DNA challenges are now increasingly embracing the new
technology as a backstop in the criminal justice system”); President’s DNA Initiative, His-
tory of Forensic DNA Analysis, http://www.dna.gov/basics/analysishistory (last visited May
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of such tests has become widely accepted and has revolutionized court
proceedings related to some criminal and most paternity suits.9  To
some extent, the availability of these tests eliminates the need for
“judging” because the tests—if performed accurately—provide virtu-
ally conclusive evidence of identity.10
Coming on the heels of DNA tests for purposes of identification,
these health-related tests might be considered a “second generation”
of genetic tests, at least in the courtroom setting.  This new use of
genetic tests, like other scientific advancements, will challenge judges
and juries as they struggle to understand the complexities of this new
scientific information, which has the potential for both misinterpreta-
tion and confusion.  The use of technology for this new purpose also
raises issues that go beyond legal procedures and scientific methods
and poses value-laden policy questions straddling the intersection of
law, science, and public policy.11  The increased use of technology
also comes at a time when judges are under attack for what some label
an “inability” to adequately understand new technologies and scien-
19, 2007) (“The past 15 years have seen tremendous growth in the use of DNA evidence in
crime scene investigations as well as paternity testing.  Today over 150 public forensic labo-
ratories and several dozen private paternity testing laboratories conduct hundreds of
thousands of DNA test[s] annually in the United States.”).
9. See, e.g., The Justice Project, Expanding Post-Conviction DNA Testing, http://
www.thejusticeproject.org/solution/post-conviction-dna.html (last visited May 19, 2007)
(“First introduced in a United States court in 1986, forensic DNA testing has profoundly
enhanced the truth-seeking function of the criminal justice system and revolutionized the
way we determine guilt or innocence.”); National Human Genome Research Institute,
DNA Forensics, http://www.genome.gov/11510211 (last visited May 19, 2007) (“The ad-
vances in DNA testing and technology have revolutionized criminal forensics.  Primarily,
DNA evidence is used for identification of either the victim or the perpetrator in criminal
cases.  However, new DNA procedures are being developed to take criminal forensics to
another level.”); Victor Walter Weedn & John W. Hicks, The Unrealized Potential of DNA
Testing, NAT’L INST. JUST., June 1998, at 1,  http://www.ncjrs.gov/pdffiles/170596.pdf (“De-
spite early controversies and challenges by defense attorneys, the admissibility of DNA test
results in the courtroom has become routine.  More than 200 published court opinions
support this use, and DNA testing standards have been developed and promulgated.”).
10. See, e.g., Sheila Jasanoff, Just Evidence: The Limits of Science in the Legal Process, 34 J.L.
MED. & ETHICS 328, 330–31 (2006) (“DNA profiling emerged in the . . . twentieth century
as the nearest thing to a failsafe method of identification in the toolkit of the forensic
sciences.  It came close to realizing the prosecutor’s dream of a method for revealing a
party’s guilt or innocence with no possibility of error.”).
11. See SHEILA JASANOFF, SCIENCE AT THE BAR, at xv (1995) (describing the questions
raised by new technologies in the courtroom as “situated at the intersection of law, science,
politics, and public policy”).
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tific concepts.12  Some of these critics have even argued for specialty
courts (e.g., science or health courts).13
In court proceedings, judges are the final arbiters of whether ge-
netic test results will play a role in any given case: judges decide
whether a test should be compelled as well as whether a test result
should be admitted into evidence.  The potential impact of decisions
to admit or compel health- or behavior-related genetic tests are wide
ranging.  How genetic information is used in the courts in these con-
texts may determine, among other things, whether individuals will be:
(1) compensated for their medical costs and pain and suffering in
malpractice, products liability, or toxic tort litigation; (2) hired to per-
form a job; (3) able to adopt a child or obtain child custody after
divorce or separation; or (4) held criminally responsible.  In the con-
text of malpractice, decisions regarding genetic tests may also deter-
12. See Stephen Breyer, Introduction to FEDERAL JUDICIAL CENTER, REFERENCE MANUAL
ON SCIENTIFIC EVIDENCE 4 (2d ed. 2000), available at http://www.fjc.gov/public/pdf.nsf/
lookup/sciman00.pdf/$file/sciman00.pdf (“[M]ost judges lack the scientific training that
might facilitate the evaluation of scientific claims or the evaluation of expert witnesses who
make such claims.”); Sophia I. Gatowski et al., Asking the Gatekeepers: A National Survey of
Judges on Judging Expert Evidence in a Post-Daubert World, 25 LAW & HUM. BEHAV. 433, 453–55
(2001) (concluding from survey results that “although judges overwhelmingly endorse the
active gatekeeping role defined by Daubert [v. Merrell Dow Pharmaceuticals, Inc.], many may
lack the scientific literacy necessitated by Daubert”); Introduction to Symposium, Translating
Science into Law: Lessons from Doctors, Judges, and Lawyers About the Use of Medical Evidence in
the Courtroom, 36 NEW ENG. L. REV. 573, 573 (2002) (noting that an “overwhelming majority
of the legal community has little knowledge of even basic scientific language or methodol-
ogy”); Paul S. Miller et al., Daubert and the Need for Judicial Scientific Literacy, 77 JUDICATURE
254, 260 (1994) (“[Daubert] has not amplified on how judges—often viewed as ‘generalists’
with massive demands placed on their limited time—are to reach the expected level of
scientific literacy.”). But see David S. Caudill & Lewis H. LaRue, Why Judges Applying the
Daubert Trilogy Need to Know About the Social, Institutional, and Rhetorical—and Not Just the
Methodological—Aspects of Science, 45 B.C. L. REV. 1, 8 (2003) (criticizing the Gatowski survey
as an inaccurate representation of judges’ understanding of science).
13. See, e.g., LeRoy L. Kondo, Untangling the Tangled Web: Federal Court Reform Through
Specialization for Internet Law and Other High Technology Cases, 2002 UCLA J.L. & TECH. 1,
47–53, 62–65 (2002), http://www.lawtechjournal.com/archives.php (arguing that special-
ized courts will increase uniformity and decrease forum shopping); Edward V. Di Lello,
Note, Fighting Fire with Firefighters: A Proposal for Expert Judges at the Trial Level, 93 COLUM. L.
REV. 473, 502–03 (1993) (“Justice Scalia has suggested that adjudication by generalist
judges of specialized issues clogs the federal docket and that specialized adjudication
might be the solution to this problem.”); COMMON GOOD, AN URGENT CALL FOR SPECIAL
HEALTH COURTS (2005), http://cgood.org/assets/attachments/130.pdf (setting forth ar-
guments for health courts and highlighting the proposal’s major supporters).
Maryland and Ohio courts recently launched an initiative called the Advanced Science
and Technology Adjudication Resource Center (ASTAR).  ASTAR is attempting to create a
national cadre of judges who will be experts on recent advances in medicine and other
scientific fields.  Press Release, Maryland Judiciary, Maryland Judiciary Takes Leading Role
in Preparing Judges for Science and Technology Issues (Oct. 25, 2005), http://
www.courts.state.md.us/press/2005/pr10-25-05a.html.
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mine whether a health care provider is liable for negligence.  In all
cases, the use may affect ex ante decisions by individuals about
whether to obtain genetic tests from their health care providers or
participate in genetic research.  When a genetic test is compelled, it
may have detrimental psychological impacts on the adult or child
tested and their potentially affected relatives.
In Part II of this Article, we report on cases in which a party re-
quested a judge to order or admit into evidence a health-related ge-
netic test.  These cases include reported judicial opinions, references
to such cases in the literature, and cases reported in a database of
settlements and jury verdicts.  In Part III, we present the results of our
survey of state and federal trial court judges who were asked how they
would respond to a series of requests to admit or compel a genetic test
for health-related purposes in a variety of hypothetical cases.  To our
knowledge, this is the first empirical study that attempts to discern
judicial perspectives on this new use of genetic tests.
In Part IV of the Article, we provide an analytical framework (“de-
cision matrix”) for judicial decisionmaking in these cases, including
considerations of the specific context of the case, the  purpose of the
test (i.e., to determine culpability, causation, damages, or sentencing),
and factors unique to these types of genetic tests and the genetic con-
dition at issue.  These factors are in part descriptive of what judges
said they considered in their responses to the hypothetical cases we
posed to them, but they also go beyond these considerations to build a
more robust and prescriptive framework for judicial decisionmaking.
In addition, the analysis illuminates doctrinal and policy tensions in
existing criminal, evidence, constitutional, and tort law—tensions that
surface when current doctrine is applied to cases involving the use of
health-related genetic tests.
Finally, in Part V, we look beyond the impact of judicial decision-
making to the broader societal issues at stake.  In this Part we explore
the competing objectives that factor into decisions to admit or compel
health-related genetic tests.  These objectives include technical accu-
racy, fair and just resolution of disputes, the preservation of tradi-
tional notions of responsibility, and the protection of privacy.  We
conclude that the in-court use of these “second generation” genetic
tests, in contrast to the first generation tests used for identity, raise
unique new challenges for judges who must decide whether to permit
the evidence.  Furthermore, we believe that appellate judges, legisla-
tors, and policymakers who establish evidentiary and procedural rules
will need to consider whether the benefits of using second generation
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genetic tests in the courtroom are worth the collateral consequences
to the legal system and our society.
II. THE SECOND GENERATION OF GENETIC TESTS IN THE
COURTROOM—GENETIC TESTS FOR HEALTH AND BEHAVIORAL
TRAITS
Over the last decade and a half scientists have made great pro-
gress in the development of genetic tests to determine whether indi-
viduals have a genetic condition and to assess their risk of developing
a genetic disease.14  Most genetic tests have been developed to assist in
diagnosis, treatment, or prevention of physical disease.  Some re-
searchers, however, have also suggested more controversial genetic
links to aggression, criminality, and addiction and have hinted at the
development of genetic tests to assist in identifying individuals who
may have a genetic proclivity to these traits and conditions.15
As the technology has developed, a number of scholars have pre-
dicted that courts will admit genetic tests into evidence to determine
an individual’s health status or predisposition to certain diseases or
behavioral traits.16  It appears, however, that the introduction of these
14. See GeneTests, supra note 1.  In addition, scientists have identified an ever-increas- R
ing number of genetically based diseases.  Economic & Social Research Council, Facts and
Figures, The Human Genome Project, fig.1, http://www.esrc.ac.uk/ESRCInfoCentre/
facts/index47.aspx?ComponentId=12670&SourcePageId=12641 (last visited May 19,
2007).  For a continuously updated database of human genes and genetic disorders, see
OMIM (Online Mendelian Inheritance in Man), http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db=OMIM (last visited May 19, 2007).
15. See, e.g., Natalie Angier, Matter Over Mind?  The Curse of Living Within One’s Genes,
N.Y. TIMES, Dec. 18, 1994, § 4, at 1 (noting that some researchers have suggested “candi-
date genes” for aggression and criminality); Human Genome Project Information, http://
www.ornl.gov/sci/techresources/Human_Genome/elsi/behavior.shtml#4 (last visited May
19, 2007) (explaining that researchers have asserted claims for a genetic basis of aggression
and impulsivity).
16. In 1990, Mark Ellinger predicted that while “so far courts have dealt with only one
relatively narrow application of DNA diagnostic technology, ‘DNA fingerprinting,’ a much
broader array of applications inevitably will need to be addressed.”  Mark S. Ellinger, DNA
Diagnostic Technology: Probing the Problem of Causation in Toxic Torts, 3 HARV. J.L. & TECH. 31,
32 (1990) (footnote omitted).  Ellinger focused on the possible uses of health- and behav-
ior-related DNA testing in toxic tort litigation. Id. at 31–32; see also Mark A. Rothstein, The
Impact of Behavioral Genetics on the Law and the Courts, 83 JUDICATURE 116, 119 (1999) (“Be-
cause of the adversary system, it is virtually certain that parties in both criminal and civil
cases will assert behavioral genetic arguments . . . .”).
In 1999, some scholars predicted that “[a]s testing methodologies become more so-
phisticated, the use of genetic test results is likely to expand, particularly in toxic tort litiga-
tion, to provide evidence of causation.”  Randi B. Weiss et al., The Use of Genetic Testing in the
Courtroom, 34 WAKE FOREST L. REV. 889, 889 (1999).
Subsequent articles discussed the use of genetic tests in tort cases, in particular in
malpractice, toxic tort, and products liability litigation. See, e.g., Gary E. Marchant, Genetic
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second generation genetic tests in litigation has been relatively slow.
There have been few judicial opinions (published or unpublished)
regarding the admission or compulsion of genetic tests for the pur-
pose of providing health information about one of the parties.  De-
spite the small number of reported judicial opinions discussing the
use of health- and behavior-related genetic tests, databases of settle-
ments and jury verdicts paint a picture of the types of cases in which
such tests are being used.  Thus far, the majority are torts cases.
A. Tort Cases—The Tip of the Iceberg
In the torts context, it appears that health-related genetic tests
are most often being used in medical malpractice cases involving birth
injury.  Typically in these cases, parents sue their obstetrician, assert-
ing that the physician’s negligence during labor and delivery caused
their newborn’s disabilities.  The physician argues that the newborn’s
disabilities are due to a genetic condition, and may seek to compel
and admit into evidence the results of genetic tests performed on the
newborn.17
Susceptibility and Biomarkers in Toxic Injury Litigation, 41 JURIMETRICS 67 (2000) (detailing
how genetic tests can be employed in toxic injury litigation); Anthony S. Niedwiecki, Science
Fact or Science Fiction? The Implications of Court-Ordered Genetic Testing Under Rule 35, 34 U.S.F.
L. REV. 295, 296 (2000) (discussing the implications of DNA tests in civil cases); Susan R.
Poulter, Genetic Testing in Toxic Injury Litigation: The Path to Scientific Certainty or Blind Alley?,
41 JURIMETRICS 211 (2001) (noting that genetic testing “could become an important part of
the proof of causation in toxic injury cases” and discussing the implicated scientific, ethi-
cal, and legal issues).
In addition to the use of genetic tests in tort litigation, some scholars have discussed or
suggested the use of such tests in criminal proceedings for the purposes of conviction or
sentencing. E.g., Symposium, The Impact of Behavioral Genetics on the Criminal Law, 69 LAW &
CONTEMP. PROBS. 1 (2006); Paul S. Appelbaum, Behavioral Genetics and the Punishment of
Crime, 56 PSYCHIATRIC SERVICES 25 (2005); Deborah W. Denno, Legal Implications of Genetics
and Crime Research, in GENETICS OF CRIMINAL AND ANTISOCIAL BEHAVIOUR 248 (Gregory R.
Bock & Jamie A. Goode eds., 1996); Marcia Johnson, Genetic Technology and Its Impact on
Culpability for Criminal Actions, 46 CLEV. ST. L. REV. 443 (1998); Cecilee Price-Huish, Com-
ment, Born to Kill? “Aggression Genes” and Their Potential Impact on Sentencing and the Criminal
Justice System, 50 SMU L. REV. 603, 612–25 (1997).
Others have speculated about the use of genetic tests in the employment setting if a
plaintiff wishes to claim that he or she has a genetic condition or predisposition that is
protected under the Americans with Disabilities Act (ADA). E.g., Mark S. Dichter & Sarah
E. Sutor, The New Genetic Age: Do Our Genes Make Us Disabled Individuals Under the Americans
With Disabilities Act?, 42 VILL. L. REV. 613 (1997); William M. Tarnow, Genetic and Mental
Disorders Under the ADA, 2 DEPAUL J. HEALTH CARE L. 291, 320–22 (1998).
17. See, e.g., Bennett v. Fieser, No. 93-1004-MLB, 1994 WL 542089, at *2 (D. Kan. Feb.
25, 1994) (ordering the plaintiff child to give blood for genetic testing); Dodd-Anderson v.
Stevens, Nos. 92-1015-MLB, 92-1016-MLB, 1993 WL 273373, at *1 (D. Kan. May 4, 1993)
(same); Harris v. Mercy Hosp., 596 N.E.2d 160, 163 (Ill. App. Ct. 1992) (holding that the
trial court did not abuse its discretion when it granted the defendant doctor’s motion to
compel the plaintiff to submit to genetic testing).
\\server05\productn\M\MLR\66-4\MLR402.txt unknown Seq: 10 18-DEC-07 15:00
2007] IMPLICATIONS OF GENETIC TESTS IN THE COURTROOM 867
Courts have also admitted genetic test results in a small number
of toxic torts/product liability cases.18  In those cases, defendants have
argued that the plaintiff’s injuries are genetically based and seek to
use genetic test results to establish that exposure to a toxic or harmful
substance or product was not the cause of the plaintiff’s injuries.  In a
few cases, plaintiffs have sought to introduce a negative test result to
refute the defendant’s claim. While parties are beginning to introduce
actual genetic test results in these contexts, it is still more often the
case that parties will introduce non-test-based genetic information19
through expert testimony often attempting to mount a “genetics
defense.”20
In a small number of toxic tort cases, parties have sought to use
biomarkers21 to help determine the impact of a toxic exposure on a
specific individual’s development of a disease or injury.22  Several of
18. See, e.g., Severson v. Allied Chems. Co., No. 1-90-CV-698517 (Cal. Super. Ct. Dec.
18, 1995) (ordering genetic testing to show whether a genetic disorder or the mother’s
exposure to a chemical solvent at work during pregnancy was the cause of plaintiff-child’s
mental retardation); Lawyers Await Written Order on DNA Testing in California Case, 3 MEA-
LEY’S EMERGING TOXIC TORTS, Apr. 21, 1994, at 6 (reporting on Severson).
19. See Hudson et al., supra note 7, at 393 (defining genetic information as “informa- R
tion about genes, gene products, or inherited characteristics that may derive from the indi-
vidual or a family member”).
20. See, for example, Jones v. NL Industries, No. 4:03CV229-M-B, 2006 U.S. Dist. LEXIS
33744 (D. Miss. Aug. 4, 2006), a case in which five families sued a lead paint manufacturer
claiming that lead poisoning caused their children’s mental disabilities.  The manufacturer
argued that the problems were genetically based and won the case. See Shelia Byrd, Missis-
sippi Families Lose Suit Against Lead Paint Maker, INS. J., Aug. 7, 2006, http://
www.insurancejournal.com/news/southeast/2006/08/07/71267.htm.  An expert for NL
Industries testified that “she conducted a detailed examination of each of the children
involved in the case and formed a genetic pedigree from her studies,” but did not intro-
duce genetic test results.  Mary Margaret Miller, Lead Paint Trial, GREENWOOD COMMON-
WEALTH, Aug. 1, 2006, http://www.zwire.com/site/news.cfm?brd=1838 (search “Advanced
search” using “Lead Paint Trial” for Headline and “2006” for the date).  The plaintiffs’
attorney in the case noted that “the children were tested for Fragile X, a genetic condition
that could cause inherited mental impairment, but the tests revealed normal genetic base-
lines.”  Shelia Byrd, Parents Angered by Defense in Lead Case, SEATTLE TIMES, July 14, 2006,
http://seattletimes.nwsource.com (search “Parents angered by defense in Lead Case”).
For a similar case, see Wintz v. Northrop Corp., 110 F.3d 508, 510 (7th Cir. 1997) (upholding
summary judgment for defendants where plaintiffs alleged that mother’s exposure to bro-
mide during pregnancy caused her child’s developmental problems but defendants argued
that the child’s genetic defect was the sole cause of the child’s injury).
21. Biomarkers are “anatomic, physiologic, biochemical, or molecular parameters asso-
ciated with the presence and severity of specific disease states . . . [and] are detectable and
measurable by a variety of methods including physical examination, laboratory assays and
medical imaging.”  Massachusetts General Hospital Center for Biomarkers in Imaging, Fre-
quently Asked Questions, http://www.biomarkers.org/NewFiles/faqs/definition.html (last
visited May 19, 2007).
22. See Bob Van Voris, Tort Lawyers Discover the Power of Genetics, NAT’L L.J., Sept. 14,
1998, at A1 (reporting that entrepreneurs have already taken advantage of this opportu-
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these cases have involved worker allegations that exposure to benzene
led to their cancer.  In these cases, plaintiffs have attempted to intro-
duce evidence showing chromosomal damage due to benzene expo-
sure (which, they argued, causes a unique type of chromosomal
damage, i.e., leaves a distinct “fingerprint”).23
Genetic test results might also play a role in the damages portion
of a civil case.  While courts typically begin their determination of life
expectancy with a standard mortality table, courts often consider a va-
riety of other information that plaintiffs or defendants may introduce
in an attempt to determine a plaintiff’s life expectancy and lifetime
earnings.24  Both evidence of a diagnosed illness and behaviors lead-
ing to diminished life expectancy, such as use of drugs, alcohol, or
cigarettes, may be admissible.25  Some legal academics have asserted
that “[i]f evidence of cigarette smoking is admissible to show that the
plaintiff’s life expectancy is lessened . . . , then evidence that the plain-
tiff was genetically predisposed to such a disorder also would seem to
be admissible.”26  Nonetheless, we did not find any judicial opinion
discussing the use of genetic tests for the purpose of determining
damages.
Although relatively few judicial opinions address a judge’s deci-
sion to admit or compel genetic tests for the purpose of determining a
party’s health status, a search of the LexisNexis database, Jury Verdicts
nity.  One company, Benchmark Genetics, established in 1997 and apparently out of busi-
ness in 2006, collected DNA samples from employees whose jobs exposed them to
hazardous chemicals, storing them for the day when they might have to use them as evi-
dence of changes in genetic structure in a personal injury lawsuit.).
23. Courts have responded inconsistently to this argument.  In one case, two defense
experts disputed plaintiff’s claim that benzene caused his leukemia by offering their opin-
ions that the plaintiff’s chromosomal changes did not match the chromosomal damage
connected to benzene exposure, the “benzene fingerprint.” Leukemia Death Action Involving
Benzene Exposure Settles In West Virginia, 7 MEALEY’S EMERGING TOXIC TORTS, Nov. 6, 1998, at
26 (reporting on Lavender v. Bayer Corp., No. 93-C-226K (W. Va. Cir. Ct. Oct. 12, 1998)).
The judge excluded both testimonies on the grounds that the theory lacked a sound scien-
tific basis. Id.  In another case, however, the court admitted into evidence the defendant’s
expert testimony that the chromosomal changes associated with benzene were not appar-
ent in plaintiff’s leukemia cells.  See Shell Oil Wins Defense Verdict In Leukemia Case; Court
Allows Testimony On Benzene ‘Fingerprint,’ 7 MEALEY’S EMERGING TOXIC TORTS, Apr. 24, 1998,
at 4 (reporting on Wells v. Shell Oil Co., No. 5:96cv282 (E.D. Tex. Mar. 2, 1998)).
24. Mark A. Rothstein, Preventing the Discovery of Plaintiff Genetic Profiles by Defendants
Seeking to Limit Damages in Personal Injury Litigation, 71 IND. L.J. 877, 885–86 (1996) [herein-
after Rothstein, Preventing the Discovery]; Mark A. Rothstein, Should Genetic Information Be
Used to Predict Life Expectancy of Plaintiffs in Torts Cases?, HOUS. LAW., Sept./Oct. 1996, at 50
[hereinafter Rothstein, Life Expectancy].
25. Rothstein, Life Expectancy, supra note 24, at 50. R
26. Rothstein, Preventing the Discovery, supra note 24, at 886. R
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and Settlements, Combined,27 between January 1, 1995 and December 31,
2005, yielded 258 cases where genetic tests or conditions were men-
tioned.28  Of those 258, over half (171) appeared to involve the use of
genetic information or genetic tests as a basis for determining liability
or damages.29  Ultimately, we were able to confirm whether genetic
testing was used in 127 of those cases.30
Of those 127 cases, 70 (55%) were in the context of medical mal-
practice; 21 (16%) involved child lead poisoning; 26 (21%) involved
negligence, and 10 (8%) were miscellaneous cases including domestic
relations and product liability/tobacco suits.  Of the 70 medical mal-
practice cases, 47 were related to birth injury.  A genetic test was per-
formed in 29 (41%) of the 70 cases.  In 26 of these malpractice cases,
the defendant requested the test be compelled or the test result be
admitted.  In each of the lead paint cases, the defendants argued that
the plaintiff’s injuries (usually developmental or neurological) were
not a result of lead paint exposure but, rather, of a genetic condition
or other factors.  In all of those 21 cases, defendants alleged that a
genetic condition caused the plaintiff’s condition but no test was actu-
ally performed.
A summary of all of the cases and the outcomes of each is pro-
vided in Table 1.  Based on the reported figures, genetic tests were
actually performed in slightly over one quarter of the total cases
(27.6%).31  While defendants were more likely to raise a genetic argu-
ment to bolster their case, they were less likely to support their allega-
tions with a genetic test than plaintiffs who raised such arguments.32
27. The database contains reports of jury verdicts and settlements from almost all fifty
states and the District of Columbia, collected from a variety of sources.  In May 2006, the
American Lawyers Media portion of the database became available exclusively on Westlaw.
28. We used “genetic!” as the search term.
29. We excluded duplicate versions of cases and cases where the issue was failure to
perform genetic testing or counseling or genetic testing for identification (paternity suits).
30. Where the case summaries in the database did not clearly explain the use of ge-
netic testing in the case (for example, a genetic expert witness was listed with no mention
of genetic testing in the summary), we attempted to contact the attorneys of both parties
for further information.
31. This figure was determined by dividing the number of cases where genetic tests
were performed (35) by the total number of cases (127).
32. This result may be due, in part, to the fact that unless a genetic test was already
performed on the plaintiff in a medical setting, the defendant would need a court order to
compel the test.
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TABLE 1: CASES IN WHICH PLAINTIFFS OR DEFENDANTS SOUGHT TO
INTRODUCE GENETIC EVIDENCE
Party seeking to Cases in which
introduce genetic genetic test





Plaintiff & 15 9
Defendant (60%)
B. Criminal Cases—A Matter of Time?
Although the use of DNA tests for purposes of establishing iden-
tity in criminal cases has become commonplace, there are almost no
reported cases where health- or behavior-related genetic tests have
been used in criminal proceedings.33  Nonetheless, there is clearly po-
tential for such use and several legal commentators have hypothesized
the use and implications of admitting into evidence genetic tests in a
variety of criminal proceedings.34
33. Despite the fact that these tests have not been introduced as evidence, parties have
introduced evidence of genetic predisposition, apparently based on family history, in a
handful of criminal cases. See, e.g., Hill v. Ozmint, 339 F.3d 187, 201–02 (4th Cir. 2003)
(defendant introduced evidence that he “suffered from a genetically based serotonin defi-
ciency, which resulted in aggressive impulses”); People v. Bobo, 3 Cal. Rptr. 2d 747, 753
(Cal. Ct. App. 1990) (psychiatrist testified that defendant’s paranoid schizophrenia re-
sulted from “[g]enetic factors, biochemical elements, and developmental experiences”);
Crook v. State, 813 So. 2d 68, 70–72 (Fla. 2002) (per curiam) (defendant introduced ex-
pert testimony that defendant’s violent rages were at least partially caused by genetic fac-
tors); State v. Johnson, 549 N.E.2d 565, 566 (Ohio Ct. App. 1989) (per curiam) (reversing
trial court’s decision to admit expert testimony that defendant committed crimes because
of “primary functional disautonomia . . . brought about by bad nutrition acting upon a
genetically predisposed person”); State v. Davis, No. M1999-02496-CCA-R3-CD, 2001 Tenn.
Crim. App. LEXIS 341, *12, *18 (Tenn. Crim. App. May 8, 2001) (defendant used expert’s
assertion that he had a “‘genetic predisposition’ for depression and mental illness” to ar-
gue that his mental condition prevented him from forming “the requisite intent to commit
first-degree murder” and other crimes); see also Nita A. Farahany & James E. Coleman, Jr.,
Genetics and Responsibility: To Know the Criminal From the Crime, 69 LAW & CONTEMP. PROBS.
115, 123–30 (2006) (describing the cases listed above as examples of a defendant offering
evidence of a behavioral predisposition).
34. See, e.g., Rothstein, supra note 16, at 119 (contending that American lawyers will use
behavioral genetics arguments before such arguments are generally accepted in the scien-
tific community due to the adversary legal system); Appelbaum, supra note 16, at 25–26 R
(speculating on the effect of introducing data from behavioral genetics research into the
criminal justice system); Denno, supra note 16, at 254 (suggesting that the legal system will R
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Most crimes require evidence of purposeful, knowing, or reckless
behavior to establish mens rea. Thus, a defendant who suffers from a
disease such as mental retardation, schizophrenia, or alcoholism35
may be able to use that disease state to mount an insanity or mens rea
defense.36  Either defense requires evidence both that the disease was
present at the time of the criminal act (actus reus) and that the dis-
ease was affecting the defendant’s thought process at that time.37  Ge-
netic tests arguably could be used to support a diagnosis, especially
when clinical experts disagree over whether the individual even has
the condition or behavioral trait at issue.  The state could also employ
genetic tests in sentencing proceedings to predict “future dangerous-
ness” if it became evident that certain genetic conditions predispose
individuals to violence.  Alternatively, such tests could be used by de-
fendants as a mitigating factor if judges were persuaded that one’s
genetic makeup reduces one’s free will.
In the late 1960s, several researchers found evidence that males
with an XYY chromosome might be predisposed to violence and crimi-
have to adapt as genetics tests become more sophisticated and scientifically acceptable);
Johnson, supra note 16, at 465–66 (proposing a new criminal defense called “genetic deter- R
minism,” which would excuse defendants from criminal liability if they could prove that
their genetics controlled their actions); Price-Huish, supra note 16, at 625–26 (concluding R
that “[t]he scientific and legal communities are on the edge of a new frontier with the
discovery of genetic explanations” for criminal behavior).
35. Farahany & Coleman, supra note 33, at 145–48. R
36. The former is an affirmative defense that can negate the requisite mens rea; the
latter operates as a complete defense if it negates a specific intent, although it could result
in the defendant being found guilty of a lesser general intent crime.  2 WAYNE R. LAFAVE,
SUBSTANTIVE CRIMINAL LAW § 9.2 (2d ed. 2003).  General intent refers to the intent to per-
form an act. Id. § 5.2(e).  All crimes, except strict liability crimes, require general intent.
Id.  Some crimes also require specific intent, i.e., “a special mental element which is re-
quired above and beyond any mental state required with respect to the actus reus of the
crime.” Id.  Murder, for example, is a specific intent crime requiring the presence of mal-
ice. Id. § 14.1(a).
37. The Model Penal Code’s insanity defense provision, entitled “Mental Disease or
Defect Excluding Responsibility,” provides that “[a] person is not responsible for criminal
conduct if at the time of such conduct as a result of mental disease or defect he lacks
substantial capacity either to appreciate the criminality [wrongfulness] of his conduct or to
conform his conduct to the requirements of law.” MODEL PENAL CODE § 4.01 (1962).  The
mens rea defense (also referred to as the “diminished capacity standard”) provides that
“[e]vidence that the defendant suffered from a mental disease or defect is admissible
whenever it is relevant to prove that the defendant did or did not have a state of mind that
is an element of the offense.” Id. § 4.02.
The element of mens rea “remains a critical element of proof in most states, and a
potential defense.”  National Mental Health Association, NMHA Policy Positions: In Sup-
port of the Insanity Defense (Mar. 7, 2004), www1.nmha.org/position/ps18.cfm.  Indeed,
the mens rea element of proof is implied in the MPC’s General Principles of Liability. See
MODEL PENAL CODE § 2.02(1).
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nal behavior.38  Defense attorneys used the studies to put forward an
XYY chromosome defense in a handful of criminal cases.39  The de-
fense, however, was later discredited as there was insufficient scientific
evidence linking the genetic trait to violent behavior.40  Since that
time, only a few reported cases have involved a request to the court to
consider genetic information in a criminal trial.41
38. Lee Ellis, Genetics and Criminal Behavior: Evidence Through the End of the 1970s, 20
CRIMINOLOGY 43, 50 (1982).
39. See Denno, supra note 16, at 249 (noting that the XYY chromosome defense was R
used unsuccessfully in five major American cases).
40. See id. at 250 (describing cases in which courts rejected the XYY chromosome de-
fense for lack of sufficient medical evidence causally linking the defect to criminal
behavior).
41. See supra note 33.  Perhaps the most publicized criminal case was that of Stephen R
Mobley who was tried for the 1991 murder of a Domino’s Pizza store manager.  Denno,
supra note 16, at 251.  Mobley’s attorneys sought to use evidence of Mobley’s “genetic R
make-up,” not as a defense, but as a mitigating factor in sentencing. Id.  Based on a family
history of violence, the defense requested both expert and financial assistance to perform
neurological testing and subsequent genetic analysis to determine whether Mobley had a
genetic mutation associated with inadequate production of MAOA (monoamine oxidase
A), a mutation allegedly associated with aggression and violence. Id. at 251–52.  The trial
court denied the defense’s request, citing a lack of acceptable scientific connection be-
tween the genetic mutation and the behavior in question. Id. at 252.  After a jury sen-
tenced Mobley to the death penalty, he appealed to the Georgia Supreme Court, in part
on the claim that the trial court erred in denying his motion for court-subsidized genetic
testing, but the court upheld the lower court ruling.  Mobley v. State, 455 S.E.2d 61, 65–66
(Ga.), cert. denied, 516 U.S. 942 (1995).  Mobley filed a habeas corpus petition, claiming his
counsel was ineffective at the sentencing phase, in part for “present[ing] an unorthodox
mitigating defense that attempted to show a possible genetic basis for Mobley’s conduct.”
Turpin v. Mobley, 502 S.E.2d 458, 463 (Ga. 1998).  A trial judge vacated his death sen-
tence, but the Georgia Supreme Court reversed on grounds that counsel had made a rea-
sonable strategic decision. Id. at 467.  The Court of Appeals for the Eleventh Circuit
agreed with the Georgia Supreme Court.  Mobley v. Head, 267 F.3d 1312, 1319 (11th Cir.
2001), cert. denied, 536 U.S. 968 (2002).  A similar case was recently heard by the Supreme
Court of the United States. See Schriro v. Landrigan, 127 S. Ct. 1933 (2007).  Jeffrey Lan-
drigan filed a petition for federal habeas corpus relief alleging that he was not provided
effective counsel because his lawyer, among other things, failed to adequately investigate
and present mitigating factors (including a genetic predisposition to violence) at his sen-
tencing hearing for a capital crime.  The district court denied Landrigan’s request for a
hearing, determining that he could not make out “a colorable claim of ineffective assis-
tance of counsel and therefore was not entitled to an evidentiary hearing.” Id. at 1937.
The Ninth Circuit determined that the district court had “abused its discretion in refusing
to grant the hearing.”  The Supreme Court reversed the Ninth Circuit but did not address
the issue of the defendant’s genetic predisposition.  The most interesting commentary on
the effect of genetic information on the sentencing decision comes from the dissent in the
Court of Appeals’s opinion.  The dissent argued that in light of the facts that Landrigan
had brutally stabbed a fellow inmate and killed a man after escaping from prison, “the
potential for future dangerousness—including peril to future fellow inmates—inherent in
Landrigan’s alleged genetic pre-disposition for violence would have negated its mitigating
capacity for evoking compassion in the sentencing judge.”  Landrigan v. Schriro, 441 F.3d
638, 652 (9th Cir. 2006) (en banc) (Bea, J., dissenting).
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III. JUDGES AS GATEKEEPERS: SURVEY OF TRIAL COURT JUDGES
Whether courts are capable of making sound decisions to admit
or compel health-related genetic test results is an open question.42
Judges and jurors, for example, may give these genetic test results
more weight than they deserve because the tests appear definitive
when, in actuality, they may be only mildly predictive of a genetic
condition.
To better understand judicial perspectives about the use of
health- and behavior-related genetic tests in court proceedings, we
conducted a survey of all state circuit court judges and federal district
court judges in Maryland.  The judges were asked whether they had
experience with requests to admit or compel genetic tests in the court-
room (either for purposes of identity or health/behavioral status);
their attitudes toward the use of DNA tests in criminal cases for deter-
mining identity; and information about their background, including
how long they had been judges, whether they had any educational
background in a natural science or engineering, and whether they
had attended any judicial education programs on genetics.  In addi-
tion, the judges were given a series of hypothetical cases and asked
whether they would admit or compel a genetic test in the circum-
stances described and, if not, to indicate the factors that influenced
their decisions.43
Several of the hypotheticals were based on actual cases, however,
in order to examine the effect of changes in a number of key vari-
ables, others were written using genetic tests for diseases or conditions
that have not yet been developed or commercialized. Factors that we
intentionally varied across the hypotheticals included: the type of re-
quest, i.e., to admit or compel the test; the context of the request, i.e.,
civil or criminal case; and the nature of the condition or disease for
which the test was requested.  The last factor varied based on whether
the disorder was physical or mental/behavioral, congenital or late on-
set, caused by a single gene or mutation or a more complex disorder,
and the likelihood that a person who has the gene mutation would
42. Some scholars have suggested that judges do not have “the necessary training, time,
or motivation” to make these types of scientific judgments.  Niedwiecki, supra note 16, at R
349 (citing Randolph N. Jonakait, Forensic Science: The Need for Regulation, 4 HARV. J.L. &
TECH. 109, 170–72 (1991)).
43. The surveys were distributed by mail between January and October 2004.  A brief
summary of the results of the study were published in the journal, Science. Diane E. Hoff-
mann & Karen H. Rothenberg, When Should Judges Admit or Compel Genetic Tests?, 310 SCI.
241 (2005).
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develop symptoms of disease or exhibit the behavioral trait related to
the mutation, i.e., the gene penetrance.44
The hypotheticals included two criminal cases, one involving con-
viction and the other sentencing, and four tort cases, two focusing on
causation and two on damages.45  In each case, judges were told that
the test met the relevant Daubert or Frye standard for admission of sci-
entific evidence.46  If the judges answered “no” to a question, i.e., they
would not admit or compel the test, they were asked how significant a
number of listed factors were to their decision.47  These factors varied
depending on the question but generally included concerns about rel-
evance, stigma, privacy, the failure of the test to indicate the serious-
ness of the disease or time of onset, whether the test was sufficiently
conclusive, and whether the jury would give the test appropriate
weight.  The exact wording of the hypothetical cases, along with a
description and analysis of judicial responses to them, are included in
the text below.48
After we collected the surveys, we met with small groups of judges
in several state circuit courts and at the federal district court to share
our results and solicit their reactions to our findings.  Along with the
survey results, selected comments from these small group meetings
are reported below.  It was often the insight of one judge that stimu-
lated us to further examine and analyze the issues raised by the survey.
44. Some individuals who have a gene mutation may never develop the disease.
Human Genome Project Information, Evaluating Gene Tests: Some Considerations, http:/
/www.ornl.gov/sci/techresources/Human_Genome/resource/testeval.shtml (last visited
May 19, 2007).  Examples include BRCA1 and BRCA2 genes, which are associated with a
rare form of breast cancer, and ApoE, a gene linked to the development of Alzheimer’s
Disease. Id.  In other cases, such as with Huntington’s disease, the genes are 100% pene-
trant and those who have the gene will develop the disease if they live to the age of onset.
Id.
45. Two additional cases, one in the context of employment discrimination where the
plaintiff sought to introduce a genetic test providing evidence that he was an alcoholic,
and one in the context of a child custody dispute where a father asked the judge to compel
the mother to have a genetic test for Huntington’s disease, were included in the study but
are not discussed in this Article.
46. While the federal courts and most states have adopted the Daubert standard for the
introduction of scientific evidence, Maryland state courts continue to apply the Frye stan-
dard. See Reed v. State, 391 A.2d 364, 372 (Md. 1978) (adopting standard announced in
Frye v. United States, 293 F. 1013 (D.C. Cir. 1923)); Clemons v. State, 896 A.2d 1059, 1065
n.7 (Md. 2006) (reiterating that “Maryland has continued to adhere to the Frye test rather
than the Daubert standard”); see also infra note 103 and accompanying text. R
47. Possible responses included: “very significant,” “somewhat significant,” “not at all
significant,” and “did not consider.”
48. The study protocol was sent to the University of Maryland Baltimore Institutional
Review Board (IRB) and was determined to meet the criteria for exemption from IRB
oversight.
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A. Response Rate and Background Data
Of 140 circuit court judges in Maryland, 101, or 72%, responded
to the written survey.  In addition, 64% of the 25 federal district court
judges in the state responded.49  In terms of prior experience with
requests to admit genetic test results or compel genetic tests, 42% of
state judges and 25% of federal judges had had a request to compel a
genetic test in a criminal case for the purpose of determining identity;
57% of state judges and 19% of federal judges had had a request to
admit such test results.  In both cases, the large majority of the judges
(93% state; 100% federal) always admitted such requests.  Both state
and federal court judges had very positive attitudes toward the use of
DNA tests for this purpose.  In response to the question, “How has the
use of DNA tests affected the fairness of the outcomes in those cases?,”
81% of state judges and 62% of federal judges responded either
“largely positively” or “somewhat positively.”  A significant majority
(76%) of state judges had ordered a DNA test in a paternity case for
the purpose of determining identity.50
Seven state court judges reported that they had received requests
to compel genetic tests for the purpose of determining health status
(i.e., the presence of a genetic disease or predisposition), and only
two state judges had received requests to admit such tests.  Of these
respondents, two had received a request to admit or compel in the
context of a criminal proceeding.  When asked for the circumstances
of each request, for the civil proceedings the types of cases included
paternity, adoption, child custody, malpractice, personal injury, and
lead paint poisoning.  No federal judge had received a request either
to compel or admit genetic tests to determine health status.
B. Results—Criminal Cases
Hypothetical #1: Criminal Case for Homicide: In a criminal homicide
case, at issue is the admission into evidence of a genetic test to show that the
49. Of those state court judges who responded, the average number of years served on
the bench was 9.4 (range: 1–27).  For federal judges, the comparable number was 11.3
(range: 0.5–37.5).  Out of the 101 state judges, five had an undergraduate degree in a
natural science or in engineering, and only one had a graduate degree in either of these
areas.  Of the federal judges, one had an undergraduate degree in a natural science or in
engineering, and none had a graduate degree in either area.  In addition, over half of the
state court judges (58%) had attended an educational program for Maryland and Dela-
ware judges held in October 1998 on “Genetics in the Courtroom,” and 16% had attended
other educational programs on genetics.  By contrast, only 25% of federal judges had at-
tended a judicial educational program focusing on genetics.
50. Federal judges were not asked to respond to the paternity question because they do
not hear paternity cases.
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defendant could not satisfy the mens rea requirement necessary to establish
criminal intent.  The defendant (age 28) requests to have admitted the results
of a genetic test showing that he has schizophrenia.
Schizophrenia is a serious psychiatric behavioral disorder.  Someone
with schizophrenia may have difficulty distinguishing between what
is real and what is imaginary, may be unresponsive or withdrawn,
and may have difficulty expressing normal emotions in social
situations.
Symptoms may develop slowly over months or years, or may appear
very abruptly.  The disease may come and go in cycles of relapse and
remission.
A person who tests positive for a gene mutation that predisposes him/
her to schizophrenia has a 50–60% probability of manifesting symp-
toms of the disease by the age of 25.
The prosecution objects to the admission of the test.
Would you admit the test results?
In response to this question, respondents were fairly evenly di-
vided, with a small majority of state court judges (54%) saying they
would admit and a somewhat larger majority of federal judges (62%)
saying they would not.  Of those who would not admit, a large major-
ity believed the results were not sufficiently conclusive, presumably be-
cause only 50–60% of individuals with the gene would manifest
symptoms by the time they reached the age of the defendant when he
committed the crime.  Other reasons given for not admitting the test
results in this scenario were that the jury would weigh the results inap-
propriately; the results would not be relevant to a determination of
guilt or innocence; and the test did not indicate how seriously the
disease would manifest.
In discussion with judges about the results, an initial hurdle for
many was whether, even if it were clear that the defendant had schizo-
phrenia at the time of the crime, the diagnosis would be sufficiently
probative to the determination of mens rea.51  Assuming that it would
51. When extreme symptoms of schizophrenia are present, “persons are said to exhibit
impaired reality testing and to be actively psychotic . . . [indicating] that some aspect of the
person’s experience would not be consensually validated by most or all of his peers.”
DAVID L. FAIGMAN ET AL., SCIENCE IN THE LAW 22 (2002) (emphasis omitted).  To negate
some or all of the mens rea required for committing the charged offense, a defendant may
offer clinical testimony to show that he did not have the capacity to form the necessary
intent required by the law. Id. at 16–17.  Some states, however, “do not permit the intro-
duction of psychiatric testimony as to any issue other than insanity, finding its use to prove
diminished capacity too speculative and unreliable.” Id. at 17 (citing GARY B. MELTON ET
AL., PSYCHOLOGICAL EVALUATIONS FOR THE COURTS: A HANDBOOK FOR MENTAL HEALTH PRO-
FESSIONALS AND LAWYERS 128–29 (1987)).  Maryland has not adopted the defense of dimin-
ished capacity; however, Maryland courts have permitted a defendant to present evidence
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be probative, the judges remained divided about whether to admit the
test.  A few judges commented that the test indicates a predisposition
for development of the disease, not whether someone has the disease.
As a result, it would not be informative on the question of whether the
defendant had symptoms at the time of the crime and, therefore,
would not be relevant.  One judge noted that the issue was not so
much one of admissibility, but rather one of how much weight to give
the test results (or how much weight to instruct the jury to give them).
Several respondents described this as a “gray area” where the ulti-
mate question would be whether the information would be more prej-
udicial than probative.  A number of judges expressed the view that
they would probably admit the test results if an expert testified regard-
ing their scientific foundation.  Some said they would be more likely
to admit the test results if there were experts on each side—one ex-
pert asserting that the defendant had schizophrenia and the other ex-
pert disputing that contention.  One judge said he would be more
likely to admit the test results if there was clinical evidence supporting
a diagnosis of schizophrenia, but would feel differently about admit-
ting the test results standing alone.  Even if an expert laid the founda-
tion, others were still unsure of the test results’ reliability, or were
concerned that a jury might find the information too confusing.  Re-
spondents had opposing views as to how a jury would interpret the test
results—some thought a jury would give them more weight than they
deserve given their questionable probative value; others thought that
juries often hear evidence of a similar nature and an expert could
help them interpret the test results.
Hypothetical #2: Criminal Case—Sentencing: Assume Case 1 has moved
on to a non-capital sentencing proceeding.  At issue is the admission of a ge-
netic test to show the future dangerousness of the defendant.  The prosecutor
requests that the defendant be compelled to have a genetic test for a gene muta-
tion that predisposes an individual to exhibit bouts of extreme rage.  (The con-
of impaired mental condition for the purpose of showing the absence of mens rea in a
specific intent crime. See Hoey v. State, 536 A.2d 622, 633 (Md. 1988) (“[W]here a particu-
lar mental element of a crime must be proved to establish the commission of a crime,
evidence that it did not exist, whether due to mental impairment or some other reason
relevant to that issue, is admissible.”).  The Fourth Circuit has held that in federal criminal
trials psychiatric evidence may still be introduced to rebut specific intent, despite the In-
sanity Defense Reform Act (IDRA) of 1984, 18 U.S.C. § 17 (2000), which seemingly nar-
rowed the admissibility of psychiatric testimony. See United States v. Worrell, 313 F.3d 867,
872–74 (4th Cir. 2002) (noting that “the IDRA does not prohibit psychiatric evidence of a
mental condition short of insanity when such evidence is offered purely to rebut the gov-
ernment’s evidence of specific intent”).
\\server05\productn\M\MLR\66-4\MLR402.txt unknown Seq: 21 18-DEC-07 15:00
878 MARYLAND LAW REVIEW [VOL. 66:858
dition is referred to as Hyde’s Syndrome.)52  As in Case 1, between 50% and
60% of individuals with this mutation exhibit these behavioral abnor-
malities before the age of 25.  With this test result the prosecutor
wishes to show that the defendant has a proclivity toward violence
(“future dangerousness”).  The defendant objects to being compelled
to have the test.
Would you compel the test?
In contrast to their responses to the first hypothetical, the large
majority of respondents (82% of state court judges and 85% of federal
court judges), said they would not compel a genetic test in a criminal
sentencing proceeding for the purpose of establishing proclivity to-
ward “future dangerousness.”  As in Hypothetical #1, respondents be-
lieved that the test was not sufficiently conclusive but, in follow-up
discussions, were also concerned about the stigma that would be cre-
ated by such a test result.  The judges thought that compelling the test
would be using an “inexact” instrument to condemn someone for life.
Using such a test, they asserted, would be tantamount to concluding
that the defendant could never “be good.” Others believed that be-
cause such a test was being used as an indicator of mental, not physi-
cal, health, it would be especially offensive and stigmatizing.
Several judges were of the view that individuals should not be
compelled to know the future against their will.  They reasoned that
such information is an invasion of one’s privacy and could have a neg-
ative psychological impact on the recipient.  One judge said he
thought judges were likely to reflect societal reluctance to “cubby
hole” people based on genetics, giving insurance as an example of this
hesitancy.  Another judge expressed concern about how the informa-
tion would be used in the future, stating that because this was in the
context of a criminal case it could become a matter of public record.
52. “Hyde’s Syndrome” is a fictitious disease.  However, researchers continue to investi-
gate the relationship between various types of real psychoses (schizophrenia, delusional
disorders, major depressive disorder, and bipolar disorder) and violence.  According to
one source,
[t]he literature is quite diverse, ranging from anecdotal reports, to investigations
of the incidence of mental illness among offender populations, to studies of the
incidence of criminal activity among persons diagnosed with psychiatric disor-
ders.  Many studies have design flaws, such as biased sample selection, questiona-
ble diagnostic validity, a limited range of predictors, or inadequate measures of
violence (criminality), all of which may contribute to inconsistent results across
studies or limit the generalizability of their findings.
FAIGMAN ET AL., supra note 51, at 30 (citing Alexander D. Brooks, The Constitutionality and R
Morality of Civilly Committing Violent Sexual Predators, 15 U. PUGET SOUND L. REV. 709, 740–50
(1992)).
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If the result could be put under seal, however, he indicated that he
might feel differently.
While most of the judges seemed reluctant to use a genetic test in
the context of sentencing, a few argued that in cases where the defen-
dant has no criminal history, this type of test might help them predict
future dangerousness.  These judges reasoned that because the defen-
dant had already been convicted, his privacy interest would be lower
than in the pre-conviction stage.  Judges, they asserted, are in the “risk
assessment” business and, as such, “need all the information they can
get in attempting to predict future behavior.”
Additionally, some judges raised the point that in the future, all
those convicted of a crime in Maryland and many other states will
have their DNA taken and stored.53  Several were troubled by this
broad-based testing because it raises the specter of studies of prison
inmates for a “violence gene.”  They realized, however, that if the test
had already been performed, there would be no need to compel it.
The issue would be whether to use it for sentencing purposes.  Several
judges expressed concern that relying on a genetic test in these cir-
cumstances would “take the judgment out of judging.”
In comparing and contrasting the results in these two hypotheti-
cals, significant variables for the judges’ decisions appeared to be
whether the request was to admit or compel, who requested the test,
and for what purpose it would be used (conviction or sentencing).
Judges were more likely to grant the request of the defendant to admit
a test for schizophrenia to show lack of intent than to grant a request
by the prosecutor to compel a test to increase a sentence. We are un-
certain  whether differences in judicial responses to the two cases
would have been as great if both were requests to admit a test result.
53. As of December 2004, all fifty states required that convicted sex offenders provide a
DNA sample, and thirty-nine states required that all convicted felons provide such a sam-
ple. See National Conference of State Legislatures, State Laws on DNA Data Banks: Qualify-
ing Offenses, Others Who Must Provide Sample (Nov. 2003), http://www.ncsl.org/
programs/health/genetics/DNAoffenses.htm (listing states requiring DNA sampling of
convicted offenders); see also ROSEMARY WALSH, PRIVACY INTERNATIONAL, THE UNITED
STATES AND THE DEVELOPMENT OF DNA DATA BANKS (Feb. 2, 2006), http://
www.privacyinternational.org/article.shtml?cmd%5B347%5D=x-347-528471 (discussing
the development of state and federal DNA databases).  These state DNA databases are
linked by the Combined DNA Index System (CODIS) operated by the Federal Bureau of
Investigation. See How Effectively Are State and Federal Agencies Working Together to Implement the
Use of New DNA Technologies? Before the Subcomm. on Gov’t Effic., Fin. Mgmt. and Intergov’t Rel.
of the H. Comm. on Gov’t Reform, 107th Cong. 49 (2001) (statement of Dwight E. Adams,
Deputy Ass’t Dir., Laboratory Div., FBI).  Most of the information in CODIS consists of
DNA profiles that only include specific segments of DNA that “do not reveal information
relating to a medical condition or disease.” Id. at 51.
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The prosecution’s request to compel the test raised concerns about
the psychosocial impact of the genetic information on the plaintiff
that would not be relevant for a request to admit a test that had al-
ready been performed in a medical setting.
C. Results—Civil Cases
Hypothetical #3: Medical Malpractice: In a malpractice case, you are
asked to compel a genetic test of a minor.  The mother of a minor brought suit
alleging that her doctor was negligent in his care of her during her labor and
delivery and, as a result, her son suffered permanent brain damage.  The physi-
cian, an Ob-Gyn, argued that the child’s condition was due to a genetic condi-
tion rather than any negligence on his part, and requested that you compel a
genetic test.  During a motion hearing on this request, a geneticist testified that
the child may suffer from Fragile X Syndrome, a genetic condition characterized
by moderate mental retardation in affected males.  The child’s mother objects to
the test.
Would you compel the test?
Hypothetical #4: Toxic Tort: Assume facts similar to Hypothetical #3;
however, rather than a malpractice suit, this is a toxic tort suit against a man-
ufacturer of solvents.  The child’s mother sues a solvent manufacturer for dam-
ages to her son resulting from her exposure to solvents at her workplace while
she was pregnant.  Her son shows some of the traits of Fragile Y Syndrome.54
Fragile Y Syndrome manifests similarly to Fragile X, however, symp-
toms only develop as a result of a combination of genetic and environ-
mental factors, i.e., only individuals with the genetic condition
develop the disease but only as a result of exposure, pre or post birth,
to certain solvents.  (These individuals have a heightened sensitivity to
the solvents.)  The defendant requests that you compel the child to
have a genetic test for the Syndrome.  The child’s mother objects to
the test.
Would you compel the test?
In the context of the civil tort hypotheticals where the defendant
was asking the judge to compel a test to establish that the defendant’s
negligence was not the cause of the plaintiff’s injury, the large major-
ity of judges said they would compel the test (85% of state judges and
75% of federal judges in the malpractice case; 71% of state judges and
77% of federal judges in the context of the toxic tort).  In these two
hypotheticals, the judges were comfortable compelling the test be-
cause, they reasoned, the plaintiff had put the health of her child at
issue and the defendant had a right to this information.  They distin-
54. “Fragile Y Syndrome” is a fictitious disease.
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guished this scenario, where the test was being used to confirm a diag-
nosis, from others where the test was being used for prediction, and
commented that compelling a test for purposes of diagnosis is a well-
established practice.  Others distinguished these cases from the prior
criminal scenarios, commenting that these cases were “only” about
money and did not implicate a liberty interest.  Several judges also
commented that although these cases did not involve a question
about the plaintiff’s mental state, when a plaintiff puts his or her
mental state at issue, but declines to consent to testing, he or she faces
sanctions and possible dismissal of the case, thus compelling the test-
ing is usually unnecessary.  One judge said that he might not admit
the test result, but he would compel it because it might promote a
settlement.
Despite the large majority who said they would compel the test in
Hypothetical #3, a few raised the point that the test would not rule out
negligence as the cause of the plaintiff’s disability; the child’s disabili-
ties could be attributed both to a genetic disorder and to negligence.
In such a case, the finding would be relevant to a determination of
damages.  The genetic condition, e.g., Fragile X, would be treated as a
preexisting condition resulting in mitigation of damages for the physi-
cian.55  The challenge in such a case would be whether a medical ex-
pert could, with any certainty, determine how much of the child’s
disability was due to negligence and how much to the genetic
condition.
In response to Hypothetical #4, in which the judge was asked to
compel a test for a complex genetic condition that manifested only as
a result of having a specific gene mutation and being exposed to a
certain solvent, judges’ reasons for compelling the test were similar to
those given for the prior hypothetical.  The distinguishing factor in
this fact pattern was that a negative test would rule out Fragile Y as the
child’s disorder and potentially any liability on the part of the defen-
dant, assuming the solvent otherwise posed no threat to the fetus.  A
positive test, however, would mean the defendant’s actions were, in
part, a cause of the child’s disorder.  In this latter scenario, most
judges seemed to agree that damages would be allocated based on the
rule that “you take your victim as you find him.”  One judge, however,
55. See, e.g., Ostrowski v. Azzara, 545 A.2d 148, 152 (N.J. 1988) (“Courts recognize that
a defendant whose acts aggravate a plaintiff’s preexisting condition is liable only for the
amount of harm actually caused by the negligence.”); see also Fosgate v. Corona, 330 A.2d
355, 357–58 (N.J. 1974) (concluding that the jury instruction that allowed damages in this
malpractice action “only to the extent of [the] aggravation or acceleration” correctly stated
the general legal principle).
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commented that juries might reduce damages, despite a jury instruc-
tion consistent with the aforementioned rule, if they believed that the
condition was not exclusively a result of the defendant’s negligence;
another person could have been exposed to the solvent and not devel-
oped the syndrome.
Hypothetical # 5: Damages—Life Expectancy: In the damage phase of a
products liability case, at issue is the compelling of a genetic test to show short-
ened life expectancy of the 21-year-old plaintiff.  The defendant requests that the
plaintiff be compelled to have a genetic test for Neurofibromatosis type II (NF-
2), as his father died of the disease at the age of 40.  NF-2 is a rare inherited
disorder characterized by the development of benign tumors on both auditory
nerves and by the development of malignant central nervous system tumors.
The disease is unrelated to the injury caused by the defendant’s product.  Virtu-
ally everyone who has the mutation develops the disease; however, the severity of
symptoms differs from person to person, and the gene is not predictive of such
disparities.  An expert witness testifies that the average age of onset of NF-2 is
between 18 and 24 and that the average age of death of those with the disease is
36.  At present, the plaintiff has no symptoms of the disease.
Would you compel the test?
Respondents were significantly divided in their response to this
request.  The majority of both state and federal judges, however, said
they would not compel the test (56% of state judges and 62% of fed-
eral judges).  The primary reason judges gave for a “no” response was
that there was not “good cause” for the test.
In discussion with judges about these results, some indicated that
the information was “too problematic” and that a jury would have a
difficult time understanding it; others believed that life tables could
be used with an instruction about the meaning of the test.  Those
troubled by compelling the test asked, “where does this stop?,” raising
concerns about the use of such tests to predict other diseases such as
breast cancer or heart disease for which the genetic component is a
relatively minor cause of the disease.  One judge said he would draw
the line based on whether or not one of the party’s parents suffered
from the disease and, as a result, there was a high background
probability that the child would have the disease.  Some asked, rhetor-
ically, “how far do we go now with trying to predict life expectancy?
Do we allow defendants to ask questions about family history such as
when the plaintiff’s parents died and what they died of?”
Others who said they would not compel the test expressed con-
cerns about the psychological impact on the plaintiff.  One said a
plaintiff given this information might commit suicide.  In response to
this sentiment, another judge said the plaintiff might be better off
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knowing that he had the gene.  Others who were uncomfortable com-
pelling the test said they saw a difference between using the informa-
tion in this hypothetical and in the prior tort cases because in this
hypothetical the information would be used to predict the future
rather than looking back to determine causation.  However, a number
of judges indicated that they would admit evidence that the plaintiff
was a smoker for the purpose of establishing that she would, more
likely than not, have a reduced life expectancy due to lung cancer and
other diseases.  One judge made the distinction that smoking is a vol-
untary activity whereas a genetic predisposition is something that a
plaintiff cannot control.
A few judges suggested compromise solutions to this case.  One
offered that the defendant could introduce the possibility of the gene
based on family history (50%), and the jury could determine damages
based on this likelihood.  As a result, damages would be less than what
they would have been if the plaintiff did not have the gene and more
than if the plaintiff had the gene.  The burden would then be on the
plaintiff to have the test if he wanted to rebut the implication that he
had the gene and argue that his damages should be higher.  Another
judge suggested that the possibility that the plaintiff had the gene
could be presented to the jury along with the fact that the plaintiff was
offered the test but declined to have it.  The plaintiff, in that case,
would then have to explain to the jury why he did not want the test.
One judge analogized this situation to cases where the plaintiff is of-
fered surgery that might reduce damages but nevertheless declines to
have it because of associated risks or concerns that it might not be
effective.
Hypothetical # 6: Damages—Pain & Suffering: Instead of the defendant
asking that a genetic test be compelled, in the damage phase of the case, the
plaintiff asks to admit genetic test results showing that he has a condition that
makes him extremely sensitive to pain.  He would like to use this information to
argue that his damages for pain and suffering should be increased.  Individu-
als with the genotype of the plaintiff have a 70% probability of manifesting the
heightened sensitivity.  The age of onset of the condition is typically early adult-
hood (18–24).  Individuals who manifest the condition experience extreme sen-
sitivity to pain and often must take heavy doses of pain medication throughout
their lives, which may only partially relieve their pain.
Would you allow the introduction of this genetic test result into evidence?
In contrast to Hypothetical #5, most judges (82% of state court
judges and 62% of federal judges) responded “yes” to the plaintiff’s
request to admit a genetic test to show increased sensitivity to pain.  A
few judges thought it would be very helpful to have a test for pain—to
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be able to turn something so subjective into something more objec-
tive.  Those who responded “no” provided the following reasons as
“very significant” to their decision: (1) the “test was not sufficiently
predictive”56 and (2) the jury would weigh the test result inappropri-
ately.57 One judge said that he would not let it in because there is no
indication that the plaintiff currently has the condition and the test
cannot tell with certainty whether he will develop it.
D. Limitations of the Data
Vignettes, by nature, lack the complexity and context surround-
ing a real case, and responding to them does not require the usual
interaction and dialogue that is part of an actual social encounter or
courtroom proceeding.58  This may have been particularly true in our
survey, which likely presented a number of judges with their first ex-
posure to some of these complex genetics issues.  This counsels cau-
tion in using the survey data to predict what judges would decide in
actual cases.  The fact that some of the judges appeared to change
their opinions after discussion in a small group setting may reflect this
dynamic.  Judges may decide differently in the courtroom where they
generally hear testimony from experts with opposing views who pro-
vide the necessary background information for more informed deci-
sions.  These judicial respondents did not have the opportunity to
hear oral argument, read briefs, converse with other colleagues, or
hear from experts before opining on the survey hypotheticals.  As a
result, their responses to the survey vignettes may not be valid predic-
tions of their ultimate judgments about these unique cases and may
represent only their initial reactions to these types of fact patterns.
Regarding generalizability, while the survey yielded a sufficient
response rate to generalize results to judges in Maryland, the results
may not be applicable to judges from other states.  The judiciary in
56. Eighty-seven percent of state court judges who responded “no” said that this was
“very significant” in their decision not to admit the test.
57. Fifty-three percent of state court judges who responded “no” said that this was “very
significant” in their decision not to admit the test.
58. See generally Dinah Gould, Using Vignettes to Collect Data for Nursing Research Studies:
How Valid Are the Findings?, 5 J. CLINICAL NURSING 207 (1996) (exploring the validity of data
derived from vignettes); Rhidian Hughes, Considering the Vignette Technique and Its Applica-
tion to a Study of Drug Injecting and HIV Risk and Safer Behaviour, 20 SOC. HEALTH & ILLNESS
381 (1998) (addressing the benefits and difficulties of vignette research, including the
criticism that vignette data ignores the necessary interaction and feedback of social life);
John W. Peabody et al., Measuring the Quality of Physician Practice by Using Clinical Vignettes: A
Prospective Validation Study, 141 ANNALS INTERNAL MED. 771 (2004) (discussing vignettes as a
tool for measuring the quality of clinical practice while also pointing out their
shortcomings).
\\server05\productn\M\MLR\66-4\MLR402.txt unknown Seq: 28 18-DEC-07 15:00
2007] IMPLICATIONS OF GENETIC TESTS IN THE COURTROOM 885
Maryland has been especially sensitive to the use of genetic informa-
tion in court proceedings.  In 1998, the Maryland Judicial Institute
held a two-day educational program for judges on genetics and ge-
netic testing, with a significant number (60%) of state court survey
respondents in attendance.59  In addition, a number of judges have
attended workshops outside the state that have included sessions on
genetic information and genetic tests.
IV. FRAMEWORK FOR JUDICIAL DECISIONMAKING
Our survey results indicate that context is crucial for judges de-
ciding these cases.  In evaluating the hypotheticals, judges appeared
to weigh multiple factors simultaneously in an attempt to reach a fair
decision.  Conceptually, they seemed to apply a framework that ini-
tially distinguished between criminal and civil settings.  In each of the
two contexts they considered a number of issues.  We used the judicial
survey responses to inform the construction of a decision matrix that
might be used by judges to evaluate these complex cases.  In the three-
dimensional matrix depicted in Figure 1, each axis indicates a sepa-
rate set of factors that we argue are essential to the judicial decision-
making process.
The vertical (y) axis (labeled “Judicial Questions”) indicates
whether the initial request made by one of the litigants is to compel a
genetic test or to admit a pre-existing test result into evidence.  The
horizontal (x) axis (labeled “Purpose of Genetic Information”) con-
tains factors relating to how the genetic information will be used, i.e.,
determining culpability or liability, causation, or consequences (i.e.,
damages in a civil case or sentence in a criminal case).  On the diago-
nal (z) axis (labeled “Genetic Factors”) are considerations relevant to
genetic tests and conditions, i.e., the scientific value of the test and the
nature of the genetic trait or condition, psychosocial issues, including
privacy and stigma, concerns about genetic determinism, and the ac-
ceptance of a new technology or new use of an existing technology.60
59. See supra note 49. R
60. An alternative configuration illustrating the complexity of the decisionmaking  pro-
cess would be based on a four-dimensional matrix with the first dimension being the judi-
cial question and the second dimension being the purpose of the test.  The third
dimension, however, would focus solely on the scientific value of the test and nature of the
genetic trait or condition, including whether the disease or condition is monogenic or
multifactorial, the gene penetrance, and the disease latency.  The fourth dimension would
capture the ethical/social issues relating to utilizing the tests in the courtroom, including
privacy, stigma, psychological issues, effects on family members, and economic implica-
tions of the genetic test result.
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ANALYTICAL FRAMEWORK
Below, we elaborate on each of these factors and attempt to de-
scribe how they might be applied in or affect judicial decisions to com-
pel or admit health-related genetic tests.  In the analysis, we also
highlight weaknesses in existing doctrinal law that appear exacerbated
when confronted with the challenge of incorporating these genetic
tests and suggest that, in some cases, these doctrines be re-examined.
A. Judicial Question: Admit or Compel?
Compelling a test, in contrast to admitting an existing test result,
was more troubling to judges in the criminal context than in the civil
context.  Although we only asked judges about compelling a test in
the sentencing phase of a criminal proceeding, where privacy rights
may be somewhat attenuated, discussions with judges revealed that
many thought that compelling a health- or behavior-related genetic
test in the conviction phase of a criminal proceeding may raise Fourth
Amendment61 privacy and other constitutional concerns.  Thus far,
61. The Fourth Amendment provides:
The right of the people to be secure in their persons, houses, papers, and
effects, against unreasonable searches and seizures, shall not be violated, and no
Warrants shall issue, but upon probable cause, supported by Oath or affirmation,
and particularly describing the place to be searched, and the persons or things to
be seized.
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no reported opinions appear to discuss the constitutionality of com-
pelling a health- or behavior-related genetic test in criminal proceed-
ings.  The jurisprudence to date has been limited to compelling a
genetic test solely for purposes of determining the identity of an
individual.
For Fourth Amendment protections to apply, the action at issue
must be considered a search.62  If deemed a search, it must be “rea-
sonable.”63  Compelling a physical specimen like blood from beneath
a person’s skin by law enforcement agents during arrest, prosecution,
or conviction, has long been considered a search for Fourth Amend-
ment purposes.64  More recent jurisprudence has expanded the crite-
ria for what constitutes a search from samples collected “beyond the
body’s surface”65 to include the collection and analysis of urine and
“deep lung” breath from a breathalyzer test.66  In making these deter-
minations, courts have considered not only the extent of bodily inva-
sion and intrusiveness of the collection process, but also the nature of
the information obtained from the sample.  In the context of urine
testing, the Supreme Court in Skinner v. Railway Labor Executives’
Ass’n67 recognized, for example, that the chemical analysis of urine
“can reveal a host of private medical facts about an employee, includ-
ing whether he or she is epileptic, pregnant, or diabetic.”68
U.S. CONST. amend. IV.
62. Id.
63. Winston v. Lee, 470 U.S. 753, 767 (1985).
64. See Schmerber v. California, 384 U.S. 757 (1966) (holding that a police-ordered
extraction of a blood sample from an arrestee suspected of drunk driving constituted a
Fourth Amendment search).  For a government intrusion to be recognized as a search, an
individual must have “an actual (subjective) expectation of privacy” in the information
obtained, and that expectation must be “one that society is prepared to recognize as ‘rea-
sonable.’”  Katz v. United States, 389 U.S. 347, 361 (1967) (Harlan, J., concurring).
65. Schmerber, 384 U.S. at 769.
66. Skinner v. Ry. Labor Executives’ Ass’n, 489 U.S. 602, 616–17 (1989).  In Skinner, the
Railway Labor Executives’ Association and other labor organizations brought suit to enjoin
regulations promulgated by the Federal Railroad Administration (FRA) that mandated
blood sampling and urine testing of railroad employees involved in certain train accidents.
Id. at 606, 612.  While the Court held that the regulations did not violate the Fourth
Amendment, id. at 634, it found that “[s]ubjecting a person to a breathalyzer test, which
generally requires the production of . . . ‘deep lung’ breath . . . implicates . . . concerns
about bodily integrity and . . . should . . . be deemed a search.” Id. at 634, 616–17.
67. 489 U.S. 602 (1989).
68. Id. at 617.  In concluding that the urine collection and testing contemplated by the
FRA regulations were “intrusions [that] must be deemed searches under the Fourth
Amendment,” the Court reasoned that “chemical analysis of urine,” while not “a surgical
intrusion into the body[,] . . . can reveal a host of private medical facts[,] . . . [and] the
process of collecting the sample . . . itself implicates privacy interests.” Id.
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While a blood test may be used for obtaining a genetic sample,
more recently the less intrusive method of taking a saliva sample or
cheek (buccal) swab is often used.  Although not technically beneath
the skin, several federal and state courts have determined that a col-
lection of epithelial cells by use of a cheek swab is a search within the
meaning of the Fourth Amendment.69  One federal district court dis-
tinguished a sample taken by cheek swab from one obtained by expec-
toration and concluded that swabbing the inside of the cheek was
“clearly a search within the skin, if not literally beneath it.”70  In con-
trast, the court determined that production of a saliva sample via ex-
pectoration is “not accompanied with the personal and private
character of voiding a urine sample”71 and does not involve any intru-
sion into the subject’s body.  Nevertheless, because of the sensitive in-
formation obtained in a saliva sample, the court concluded that it
constituted a search under the Fourth Amendment.72
To satisfy the “reasonableness” requirement under the Fourth
Amendment, courts have generally required that law enforcement
agents obtain a judicial warrant73 supported by probable cause.74
69. See United States v. Nicolosi, 885 F. Supp. 50, 55–56 (E.D.N.Y. 1995) (determining
that while a cheek swab to obtain genetic information was not as intrusive as a blood test, it
implicates “dignitary interests” and therefore requires Fourth Amendment constitutional
protection).  The court in Nicolosi determined that collection of a saliva sample fell
“squarely in the middle” of a continuum of physical evidence based on the invasion of
privacy and dignitary interests at stake. Id. at 55.  On one end of the spectrum, the court
assigned items within the public domain, such as voice, hair, or handwriting samples, that
do not require a “full Fourth Amendment procedure.”  Id. On the other end, the court
placed blood and other internal bodily fluids that have to be extracted from the body and
that clearly constitute a search. Id.; see also In re Shabazz, 200 F. Supp. 2d 578 (D.S.C. 2002)
(holding that a subpoena requiring submission of a saliva sample for DNA testing was a
Fourth Amendment search); State v. Ostroski, 518 A.2d 915, 920 (Conn. 1986)
(“[B]ecause the acquisition of . . . the saliva is a search, the [F]ourth [A]mendment re-
quires that the state establish probable cause.” (citations omitted)).
70. Nicolosi, 885 F. Supp. at 55–56.
71. Id. at 56.
72. Id. The court considered the “significant amount of genetic identity information”
a saliva sample provides. Id. at 55.
73. See Schmerber v. California, 384 U.S. 757, 770 (1966) (“[W]arrants are ordinarily
required for searches of dwellings, and, absent an emergency, no less [is] required [for]
intrusions into the human body . . . .  The importance of informed, detached and deliber-
ate determinations of the issue whether . . . to invade another’s body in search of evidence
of guilt is indisputable and great.”).
74. See U.S. CONST. amend. IV (“[N]o Warrants shall issue, but upon probable
cause . . . .”).  At least one federal court and several state courts have required probable
cause to obtain a cheek swab in the context of arrest. See, e.g., Nicolosi, 885 F. Supp. at
55–56 (“[T]his is a case where the determination whether the right of privacy must reason-
ably yield to the right of search is . . . to be decided by a judicial officer upon a proper
showing of probable cause.” (internal quotation marks omitted)); State v. Ostroski, 518
A.2d 915, 920 (Conn. 1986) (noting that the acquisition of a saliva sample is a Fourth
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However, courts have also found searches of the body to be reasona-
ble when conducted without a warrant if the intrusion into the body
was minor and there was probable cause for the search.75  On occa-
sion, courts have determined that a warrant alone is insufficient.  For
example, in Winston v. Lee,76 the Supreme Court held that, despite
obtaining a court order compelling the defendant to undergo surgery
to remove a bullet lodged under his collarbone, the proposed
Amendment search, thereby requiring the state to establish probable cause); Pyle v. State,
645 P.2d 1390 (Okla. Crim. App. 1982) (holding a saliva sampling to be a reasonable
search where the state’s search warrant was based on probable cause).  While this is the
general rule, in response to a grand jury subpoena or non-testimonial identification order,
courts have held that individualized suspicion and/or reasonableness is sufficient without
probable cause. See, e.g., In re Shabazz, 200 F. Supp. 2d 578 (holding that a grand jury
subpoena ordering a saliva sample was a reasonable search because it was based on “rea-
sonable individualized suspicion” and reasonable procedures were to be used to obtain the
sample); In re Grand Jury Proceedings Involving Vickers, 38 F. Supp. 2d 159, 167–68
(D.N.H. 1998) (finding a grand jury subpoena requesting saliva samples reasonable and
therefore enforceable); Henry v. Ryan, 775 F. Supp. 247 (N.D. Ill. 1991) (holding that
individualized suspicion, not probable cause, was the appropriate requirement where a
detainee was compelled by grand jury subpoena to produce blood and saliva samples);
Bousman v. Iowa Dist. Court, 630 N.W.2d 789, 798 (Iowa 2001) (finding a nontestimonial
identification order for a saliva sampling constitutionally based on a finding of “reasonable
grounds to suspect” rather than upon a showing of probable cause); In re Nontestimonial
Identification Order Directed to R.H., 762 A.2d 1239 (Vt. 2000) (holding that federal and
Vermont constitutional search and seizure provisions do not require a demonstration of
probable cause to obtain a nontestimonial order for saliva).  Moreover, in the context of
evidence in administrative or regulatory proceedings, courts have held that individualized
suspicion is not necessarily required.  For the most part, these cases have been analyzed
using a “special needs” test, i.e., a suspicionless search may be allowed where the search is
designed to serve the government’s “special needs” beyond the normal need for law en-
forcement. See, e.g., Skinner v. Ry. Labor Executives’ Ass’n, 489 U.S. 602, 620 (1989) (not-
ing that the government agency’s interest in regulating the conduct of railroad employees
to ensure safety presents “special needs” that may justify deviations from the customary
warrant and probable cause requirements).
75. While a warrant is generally required, courts have also established a number of
exceptions to the requirement, such as exigent circumstances in which evanescent evi-
dence might otherwise deteriorate or disappear, like alcohol in the blood stream. See, e.g.,
Schmerber, 384 U.S. at 770–71 (finding that a compulsory, reasonably conducted blood test
performed without a warrant but incident to arrest was reasonable because there was prob-
able cause to suspect defendant was under the influence of alcohol and a reasonable belief
that an emergency existed that threatened to destroy the evidence); United States v. Berry,
866 F.2d 887, 891 (6th Cir. 1989) (“Because evidence of intoxication begins to dissipate
promptly, it is evident in this case that there were exigent circumstances indicating the
need to take [the blood sample].”); United States v. Snyder, 852 F.2d 471, 473–74 (9th Cir.
1988) (noting that exigent circumstances existed at the time blood was extracted from the
defendant driver).  Moreover, minor bodily intrusions in which the procedure is routine,
harmless, and performed by medical personnel do not violate the Fourth Amendment.
See, e.g., Cupp v. Murphy, 412 U.S. 291 (1973) (holding that a warrantless search of defen-
dant’s fingernails was constitutionally justified because the search was supported by proba-
ble cause, very limited in nature, and necessary to preserve potentially fleeting evidence).
76. 470 U.S. 753 (1985).
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“search” was unreasonable because the state failed to justify its intru-
sion “upon an area in which our society recognizes a significantly
heightened privacy interest.”77  In arriving at its conclusion, the Court
declared that “[t]he reasonableness of surgical intrusions beneath the
skin depends on a case-by-case approach, in which the individual’s in-
terests in privacy and security are weighed against society’s interests in
conducting the procedure.”78  The Winston Court placed less empha-
sis on the risk of the surgery than on the intrusion of the defendant’s
privacy interests from forced anesthesia and the surgical procedure,
and on the failure of the state to demonstrate a compelling need for
the information.
In most cases, once a DNA sample is obtained, law enforcement
personnel may have sufficient evidence to arrest and prosecute a sus-
pect without needing to know anything about the person’s health sta-
tus or predisposition to disease or behavioral traits.  While it is
difficult to imagine a case where the prosecution would seek an order
compelling a health- or behavior-related genetic test in the arrest and
investigatory phase of a criminal proceeding, one might envision a
case where there is no DNA evidence tying the suspect to the crime
but the prosecution theorizes, based on evidence at the crime scene
or eyewitness accounts, that it is highly likely that the person who com-
mitted the crime had a relatively rare genetically based condition that
could assist in identifying that individual.79
In such a case, prosecutors would face the hurdle of satisfying the
probable cause requirement.  If probable cause could be established,
courts might struggle with the application of the existing Fourth
Amendment “reasonableness” test to compelling a health-related ge-
netic test.  In fact, in a relatively recent case, the Supreme Court was
challenged to rethink its Fourth Amendment jurisprudence in light of
new technology allowing increased surveillance of individual behav-
ior.80  As a result of the unique privacy issues raised by health- or be-
77. Id. at 766–67.
78. Id. at 760.  The Court considered several factors used to analyze reasonableness in
the context of bodily searches including “the extent to which the procedure may threaten
the safety or health of the individual” and “the extent of intrusion upon the individual’s
dignitary interests in personal privacy and bodily integrity,” and weighed those factors
against “the community’s interest in fairly and accurately determining guilt or innocence.”
Id. at 761–62.
79. For example, an individual might have a rare, genetically based allergic reaction to
a chemical or food, or could have a genetic predisposition to a rare behavioral disorder
with certain signature characteristics.
80. See Kyllo v. United States, 533 U.S. 27, 29, 34 (2001) (characterizing its charge as
determining the limits upon the power of a new technology (thermal imaging) to “shrink
the realm of guaranteed privacy”).
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havior-related genetic information, the appellate courts may need to
re-examine the reach of the Fourth Amendment and the contours of
personal privacy.81  Little consideration has been given to personal
and family privacy interests in information obtained from the sample
in the context of determining reasonableness.  Health- and behavior-
related genetic tests arguably reveal more private facts about an indi-
vidual than DNA tests used for purposes of identification.82  Moreo-
ver, they can be distinguished from the blood and urine tests that seek
to provide evidence of substances such as alcohol or drugs that are
only temporarily in the body.  Genetic tests reveal evidence of immu-
table characteristics as well as information about third parties who do
not have a voice in whether or not this information is disclosed.
At some point in the future, courts may also confront the ques-
tion of whether the Fourth Amendment applies to the taking of a pre-
existing tissue sample from a tissue bank rather than compelling the
sample from an individual.  In such a scenario, if the sensitive nature
of the information is the basis for the determination of a “search,”
then conducting health- or behavior-related genetic tests on the sam-
81. Other authors have also recommended a need for a revised interpretation of the
Fourth Amendment in light of numerous new technologies. See, e.g., Stephen E. Hender-
son, Nothing New Under the Sun?  A Technologically Rational Doctrine of Fourth Amendment
Search, 56 MERCER L. REV. 507 (2005) (discussing the “reasonable expectation of privacy”
requirement and arguing that the “third party doctrine” must be narrowly construed if the
Fourth Amendment is to meaningfully limit government intrusions).  Because a state’s
constitution may impose more stringent standards on searches and seizures than those
required by the United States Constitution, state judges and lawmakers may also want to
examine this issue. See, e.g., Graves v. State, 708 So. 2d 858, 861 (Miss. 1997) (“[T]he
Mississippi Constitution extends greater protections of an individual’s reasonable expecta-
tion of privacy than those enounced under Federal law.”); Commonwealth v. Waltson, 724
A.2d 289, 292 (Pa. 1998) (noting “enhanced privacy rights” in the Pennsylvania
Constitution).
82. See Justin A. Alfano, Note, Look What Katz Leaves Out: Why DNA Collection Challenges
the Scope of the Fourth Amendment, 33 HOFSTRA L. REV. 1017, 1032 (2005).  Alfano notes:
[T]he DNA used by law enforcement is used exclusively for identification pur-
poses.  The thirteen core STR loci used in criminal offender databases are each
found on non-genic stretches of DNA known as “junk DNA” not linked to any
genes that would permit an onlooker to discern any socially stigmatizing condi-
tions or private medical facts.
Id. (citing United States v. Kincade, 379 F.3d 813, 818 (9th Cir. 2004)); see also David H.
Kaye, Bioethics, Bench, and Bar: Selected Arguments in Landry v. Attorney General, 40
JURIMETRICS 193, 203–04 (2000) (explaining that a Massachusetts DNA databanking law
would not likely have infringed on genetic privacy); D.H. Kaye, The Constitutionality of DNA
Sampling on Arrest, 10 CORNELL J.L. & PUB. POL’Y 455, 461–62 (2001) [hereinafter Kaye,
Constitutionality] (stating that the analysis of DNA sequences collected for law enforcement
purposes “disclose[s] nothing about the individual’s susceptibility to diseases, bodily struc-
ture, or mental functioning”).  Kaye notes that “[s]ome states expressly prohibit use of
more informative loci.” Id. at 462 n.22 (citing VT. STAT. ANN. tit. 20, § 1937(b) (1998)).
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ple would appear to constitute a search subject to Fourth Amendment
protections.
Compelling genetic tests that reveal behavioral traits or predispo-
sition to mental illness may also raise legal and normative questions
about the use of self-incriminating evidence and due process con-
cerns.  While the Supreme Court has determined that bodily invasions
implicate the Fourth Amendment,83 the Court held in Schmerber v. Cal-
ifornia that such procedures do not implicate the Fifth Amendment
self-incrimination protections.84  Relying on the testimonial versus
noncommunicative evidence dichotomy, the Court concluded that
the privilege against self-incrimination applies only to testimonial evi-
dence, i.e., compelled communications that convey factual assertions
or disclose information.85  While the framework applied in Schmerber
would appear to rule out a Fifth Amendment defense by an individual
who was compelled to provide a bodily sample for a health-related
genetic test, one might argue that cases like Schmerber, in which the
government was attempting to extract the defendant’s blood to deter-
mine if it contained alcohol, are distinct from cases involving genetic
83. See, e.g., Winston v. Lee, 470 U.S. 753 (1985) (holding that a government-ordered
intrusion to force defendant to undergo surgery to remove evidence of a crime would not
be a reasonable search permitted by the Fourth Amendment); Schmerber v. California,
384 U.S. 757, 772 (1966) (applying Fourth Amendment scrutiny to a minor bodily invasion
by law enforcement agent but ultimately finding no Fourth Amendment violation).
84. Schmerber, 384 U.S. at 760–61.  The Self Incrimination Clause of the Fifth Amend-
ment states that “No person . . . shall be compelled in any criminal case to be a witness
against himself . . . .” U.S. CONST. amend. V, cl. 3.  The Court in Schmerber held:
[T]he [Fifth Amendment] privilege protects an accused only from being com-
pelled to testify against himself, or otherwise provide the State with evidence of a
testimonial or communicative nature, and that the withdrawal of blood and use of
the analysis in question in this case did not involve compulsion to these ends.
384 U.S. at 760–61 (footnote omitted).
85. Schmerber, 384 U.S. at 761 & n.5; see also, e.g., Gilbert v. California, 388 U.S. 263,
266–67 (1967) (rejecting defendant’s claim that a sample of his handwriting was privileged
under the Fifth Amendment because “[a] mere handwriting exemplar, in contrast to the
content of what is written, like the voice or body itself, is an identifying physical characteris-
tic outside its protection”).  In addition, the refusal to submit to a blood-alcohol test has
been adjudicated to be outside the protection of the Fifth Amendment. See, e.g., South
Dakota v. Neville, 459 U.S. 553, 563–64 (1983) (“Given, then, that the offer of taking a
blood-alcohol test is clearly legitimate, the action becomes no less legitimate when the State
offers a second option of refusing the test, with the attendant penalties for making that
choice.”); Deering v. Brown, 839 F.2d 539, 543–44 (9th Cir. 1988) (extending the Neville
holding to situations where the refusal to submit to a breathalyzer test is made a criminal
offense with attendant penalties). Contra Commonwealth v. McGrail, 647 N.E.2d 712, 714
(Mass. 1995) (“Because the refusal [evidence], in essence, constitutes testimony concern-
ing the defendant’s belief on a central issue to the case, we conclude that the evidence of
the defendant’s refusal to submit to a field sobriety test constitutes testimonial or commu-
nicative evidence.”), overruled on other grounds by Commonwealth v. Blais, 701 N.E.2d 314,
318 n.3 (Mass. 1998).
\\server05\productn\M\MLR\66-4\MLR402.txt unknown Seq: 36 18-DEC-07 15:00
2007] IMPLICATIONS OF GENETIC TESTS IN THE COURTROOM 893
testing.  In the latter, the government would be compelling a test not
to offer evidence of a foreign substance contained in the defendant’s
blood or other bodily fluids or tissues, but rather to show that one’s
genetic makeup causes some people to be more apt to engage in cer-
tain unlawful (dangerous) conduct.  Cases where law enforcement
personnel are searching for foreign substances also differ from
searches for a person’s genes.  The former involves the product of a
voluntary act, while the latter is something individuals cannot control.
Information obtained from genetic tests is also distinct from informa-
tion obtained from fingerprints,86 as the former may include highly
personal-relational and health matters that are unrelated to identifica-
tion.87  Thus, although the Court has not yet determined whether
such genetic information constitutes “self-incriminating” evidence
protected under the Fifth Amendment, this type of information is dis-
tinguishable from the evidence involved in prior Supreme Court
rulings.
Compelled health-related genetic testing may also implicate the
due process protections of the Fifth and Fourteenth Amendments, in
particular, an individual’s liberty interests.  Such interests may include
protection from certain types of bodily invasions as well as the collec-
tion, for public purposes, of private and highly personal information.
While minor bodily intrusions are unlikely to trigger due process pro-
tections,88 there is a possibility that the Due Process Clause could be
interpreted to protect private, potentially stigmatizing, genetic infor-
mation.89  Here, as above, the new use of this technology pushes the
86. Obtaining fingerprints from individuals suspected of a crime has long been permis-
sible under the Fifth Amendment. See, e.g., Schmerber, 384 U.S. at 764 (“[B]oth federal and
state courts have usually held that [the Self Incrimination Clause] offers no protection
against compulsion to submit to fingerprinting . . . .”); United States v. Thomann, 609 F.2d
560, 562 (1st Cir. 1979) (“Fingerprint evidence does not fall within the [F]ifth
[A]mendment’s privilege against self-incrimination.  Compelling a criminal suspect to ex-
hibit his identifying physical characteristics, such as a blood sample or fingerprints, is not
the forced extraction of testimonial or communicative evidence contemplated by the
[F]ifth [A]mendment.”).
87. Such information, which may at some future time include proclivity to aggression,
mental illness, or alcoholism, could cause grave injury to a person’s reputation. See, e.g.,
Collins et al., supra note 4, at 844 (noting the “history of misunderstanding and stigmatiza- R
tion” in “research into the genetic contributions to traits and behaviours”); Lawrence O.
Gostin, Health Information Privacy, 80 CORNELL L. REV. 451, 490 (1995) (“Disclosure of some
conditions can be stigmatizing, and can cause embarrassment, social isolation, and a loss of
self-esteem.”); see also infra note 144 and accompanying text. R
88. See, e.g., Breithaupt v. Abram, 352 U.S. 432, 439–40 (1957) (finding that the Due
Process Clause does not invalidate defendant’s conviction based upon evidence of an invol-
untary blood test because applying a blood test is “so slight a[ ] [bodily] intrusion”).
89. See Kaye, Constitutionality, supra note 82, at 470–71 (analyzing the application of the R
Due Process Clause to state efforts to disclose highly personal information).
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envelope of existing constitutional jurisprudence and may give judges
pause when deciding whether to grant a motion to compel such tests.
The difference between compelling testing and admitting an ex-
isting genetic test result is also important in the civil context.  The
ability of courts in civil cases to compel genetic testing is based on
Rule 35 of the Federal Rules of Civil Procedure90 or an equivalent
state law.  Under Rule 35, a court may order a party to submit to a
physical or mental examination.91  Most often, defendants employ
Rule 35 to rebut plaintiffs’ allegations of physical or psychological in-
juries.92  A possible sanction for failure to comply with an order for a
medical exam is dismissal of the case.93  In addition to its use to com-
pel genetic testing, Rule 35 has been used in other troublesome ways
such as compelling psychological exams related to sexual trauma and
HIV tests.94
In deciding whether to compel an examination under Rule 35,
courts must determine whether the party subject to the examination
has placed her mental or physical condition “in controversy” and
whether “good cause” exists for the exam.95  “Good cause” requires a
factual showing that there is a need for the examination and that
there is no less intrusive means available for obtaining the informa-
tion.96  In considering the intrusiveness of the examination, courts
generally only consider the physical health risks to the examinee, al-
though a few courts have considered the psychological and emotional
trauma that may accompany a physical or mental exam.97  Courts
90. FED. R. CIV. P. 35.
91. Id.
92. See Niedwiecki, supra note 16, at 295. R
93. See, e.g., Bodnar v. Bodnar, 441 F.2d 1103, 1103–04 (5th Cir. 1971) (per curiam)
(affirming the district court’s dismissal where appellant refused to submit to a court-or-
dered mental examination).
94. See Niedwiecki, supra note 16, at 299. R
95. FED. R. CIV. P. 35 (requiring condition to be “in controversy” and court order to be
made “only on motion for good cause shown and upon notice to the person to be
examined”).
96. See Schlagenhauf v. Holder, 379 U.S. 104, 118 (1964) (“[W]hat may be good cause
for one type of examination may not be so for another.  The ability of the movant to obtain
the desired information by other means is also relevant.”); see also 8A CHARLES ALAN
WRIGHT ET AL., FEDERAL PRACTICE AND PROCEDURE § 2234.1 (1994) (quoting Schlagenhauf in
articulating the “good cause” standard).
97. See, e.g., Doe v. Roe, 526 N.Y.S.2d 718, 722 (N.Y. Sup. Ct. 1988).  In Doe, the court
stated:
While there is no consensus under what circumstances the extraordinary remedy
[of] involuntary testing should take place, it is clear that the medical,
psychosocial, and legal ramifications of such testing place it on an entirely differ-
ent plane than other, non-invasive or minimally invasive procedures.  This infor-
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often “justify their rulings by stating that the ordered testing is neces-
sary to promote a fair and judicious conclusion to the dispute.”98
In Harris v. Mercy Hospital,99 one of the few reported cases where a
genetic test was compelled, the court focused primarily on the physi-
cal intrusiveness of the procedure, commenting that blood tests are
routine procedures in everyday life.100  The court appeared to ignore
the plaintiff’s arguments that the test would subject the minor to
“trauma, serious complications from contamination or infection, and
[the] risk of [AIDS].”101  Nor did it consider the fact that the blood
test had only a 50% likelihood of indicating that the child had the
genetic defect as a reason not to compel the test.102
In cases where an individual was already tested in the context of
medical treatment, diagnosis, or research, a judge may be asked to
determine whether the results should be admitted.  To be admissible,
evidence must meet the relevant Daubert or Frye standard of the juris-
diction,103 must not be protected by a privilege, and must be relevant.
In the case of medical tests, in some jurisdictions a genetic test per-
formed by a physician for the purpose of diagnosis or treatment may
mation must be taken into account whenever an involuntary AIDS test is sought,
and must be part of the balancing process in which a court engages.
Id.
98. Niedwiecki, supra note 16, at 306. R
99. 596 N.E.2d 160 (Ill. App. Ct. 1992).
100. Id. at 163.  In Harris, the mother of a minor brought suit against physicians and a
hospital alleging that their negligent care and treatment during her labor and delivery
caused permanent brain damage to her daughter. Id. at 161.  During discovery, a geneti-
cist who previously examined the child as part of her medical care testified that she may
suffer from Angelman Syndrome, a disorder believed to involve a chromosomal abnormal-
ity. Id.  Based upon the geneticist’s testimony, a defendant physician sought to establish
that the child’s condition was caused by a genetic disorder, rather than the physician’s
negligence, and filed a motion to order the plaintiff to submit to a chromosomal blood
test. Id.  After finding “good cause” for the blood test, the trial court granted the physi-
cian’s motion. Id. at 162.  The plaintiff refused to comply with the order.  As a result, the
court held plaintiff’s counsel in civil contempt and imposed a ten-dollar fine. Id.  The trial
court’s decision to compel the order was upheld on appeal. Id. at 163.
101. Id. at 162.
102. Id. at 163; see also Bennett v. Fieser, No. 93-1004-MLB, 1994 WL 542089, at *2 (D.
Kan. Feb. 25, 1994) (imposing a Rule 35 order for withdrawal of 5 cubic centimeters of
blood from a minor child for genetic testing because the amount of blood was small, the
pain would be relatively minor, and the result was relevant to the outcome of the case).
103. Under the Frye standard, judges are generally deferential to scientists.  Once a fact
achieves “general acceptance” in the field, it can be admitted into evidence and relied
upon by expert witnesses.  Frye v. United States, 293 F. 1013, 1014 (D.C. Cir. 1923).  How-
ever, in 1993, the Supreme Court in Daubert v. Merrell Dow Pharmaceuticals, Inc. expressly
rejected the Frye test for federal court litigation and created a greater role for judges as
“gatekeepers.”  509 U.S. 579, 587–89 (1993).  Under the Daubert standard, judges are re-
quired to evaluate the reliability and scientific validity of scientific information before de-
ciding whether to admit it as evidence. Id. at 594–95.
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be inadmissible as a result of a physician-patient privilege.104  Al-
though the majority of states have such a privilege, in some states it
applies only to information revealed to a psychiatrist or other mental
health professional.105  In addition, some states recognize an excep-
tion where the patient is a litigant and puts her physical or mental
health at issue.106
The test result would be relevant if it would make some fact that
is of consequence to the outcome of the case (guilt, innocence, or
liability) more or less probable.  The probative value of a genetic test
result may depend on a variety of factors including the accuracy and
reliability of the test, the penetrance of the gene, the impact of envi-
ronmental causes on the expression of the gene, and the severity of
the disease.107
Judges generally admit such evidence if they determine it to be
relevant.  Even if relevant, however, judges may exclude the evidence
if they determine that it would be unfairly prejudicial because of its
tendency to inflame or confuse the jury.108  Thus, a judge will exclude
104. McCormick’s treatise on evidence explains the application of the physician-patient
privilege as follows:
Statutes conferring a physician-patient privilege vary extensively, though
probably a majority follow the pioneer New York and California statutes in ex-
tending the privilege to “any information acquired in attending the patient.”  Un-
derstandably, these provisions have been held to protect not only information
explicitly conveyed to the physician by the patient, but also data acquired by ex-
amination and testing.  Other statutes appear facially to be more restrictive and to
limit the privilege to communications by the patient.  This appearance, however,
may frequently be misleading, for statutes of this sort have been construed to
provide a privilege fully as broad as that available elsewhere.
1 MCCORMICK ON EVIDENCE § 100, at 455–56 (6th ed. 2006) (footnotes omitted).
105. Id.; see MD. CODE ANN., CTS. & JUD. PROC. § 9-109(b), 9-109.1(b) (LexisNexis 2006);
see also Butler-Tulio v. Scroggins, 774 A.2d 1209, 1216 (Md. Ct. Spec. App. 2001) (noting
that “there is no physician-patient privilege in Maryland”).
106. See BARRY R. FURROW ET AL., HEALTH LAW 154 (2d ed. 2000).
107. See John C. Childs, Toxicogenomics: New Chapter in Causation and Exposure in Toxic Tort
Litigation, 69 DEF. COUNS. J. 441, 444 (2002) (discussing some of the “confounding factors,
such as the potential synergistic or additive effects of other genetic, toxic or environmental
influences on the body” involved in assessing genetic test results); Niedwiecki, supra note
16, at 351–52 (discussing the “uncertainties” for courts weighing the probative value of R
genetic test results).
108. FED. R. EVID. 403 (“Although relevant, evidence may be excluded if its probative
value is substantially outweighed by the danger of unfair prejudice, confusion of the issues,
or misleading the jury, or by considerations of undue delay, waste of time, or needless
presentation of cumulative evidence.”); see also Hines v. Joy Mfg. Co., 850 F.2d 1146, 1154
(6th Cir. 1988) (clarifying that exclusion of evidence at a court’s discretion still requires a
showing that the evidence is “more than damaging to the adverse party; it must be unfairly
prejudicial”); Jackson v. Firestone Tire & Rubber Co., 788 F.2d 1070, 1075 (5th Cir. 1986)
(“Determinations of whether to exclude even relevant evidence because of its potential for
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evidence if she distrusts the jury’s ability to evaluate it properly.109  In
the case of a genetic test, a judge might exclude evidence if he decides
that a jury would find it too confusing or give it too much weight (e.g.,
decide that someone with a genetic condition or predisposition is
more likely to commit a crime, simply by virtue of that fact alone).
Other rules of evidence may also prevent the introduction of ge-
netic tests linked to certain kinds of information.  For example, the
Federal Rules of Evidence prohibit the introduction of character evi-
dence, i.e., evidence probative of a certain behavioral trait, to show
propensity to behave in a certain way.110  This may be of particular
significance for efforts in criminal cases to admit genetic tests indicat-
ing a predisposition to a behavioral trait such as aggression, impulsive-
ness, or addiction.111
Judges in civil cases may also be less likely to compel a genetic test
than to admit a test result.  However, other factors may be more signif-
prejudicial or inflammatory effects upon the jury are made by balancing inflammatory po-
tential against the likely probative value of the evidence.”).
109. See Empire Gas Corp. v. Am. Bakeries Co., 646 F. Supp. 269, 276 (N.D. Ill. 1986)
(“‘[U]nfair prejudice,’ within the context of Rule 403, means undue tendency to suggest
decision on an improper basis, commonly, though not necessarily, an emotional one.  Gen-
erally, . . . the danger of unfair prejudice . . . always exists where [evidence] is used for
something other than its logical probative force.” (citation omitted)).  A judge, however,
will often admit, with limitations, complex statistical evidence if a qualified expert can ex-
plain the evidence to the jury using precise, understandable language. FED. R. EVID. 702;
see also Kumho Tire Co. v. Carmichael, 526 U.S. 137, 151–52 (1999) (instructing that the
Daubert gatekeeping standard applies beyond purely scientific testimony to skill- or experi-
ence-based testimony because its purpose “is to make certain that an expert, whether bas-
ing testimony upon professional studies or personal experience, employs in the courtroom
the same level of intellectual rigor that characterizes the practice of an expert in the rele-
vant field”).
110. Rule 404(a) generally does not allow the introduction of “[e]vidence of a person’s
character or a trait of character . . . for the purpose of proving action in conformity there-
with on a particular occasion.” FED. R. EVID. 404(a).  There are, however, exceptions to
this rule in the criminal context.  Under Rule 404(a)(1) the prosecution is allowed to
introduce character evidence of the accused when the accused attacks a pertinent trait of
character of the alleged victim. FED. R. EVID. 404(a)(1).  Also, in a homicide case, under
Rule 404(a)(2) the prosecution is allowed to introduce evidence of the “character trait of
peacefulness of the alleged victim” in order to “rebut evidence that the alleged victim was
the first aggressor.” FED. R. EVID. 404(a)(2).  Notably, Rule 404 only allows proof of char-
acter by way of reputation or opinion. FED. R. EVID. 405(a).
111. See Appelbaum, supra note 16, at 26 (“Genetic data may even run afoul of standards R
for admissibility of evidence, because guidelines such as the Federal Rules of Evidence
exclude testimony aimed solely at demonstrating that the defendant has a propensity to
behave in a particular way.”). But see Steven I. Friedland, The Criminal Law Implications of the
Human Genome Project: Reimagining a Genetically Oriented Criminal Justice System, 86 KY. L.J.
303, 334, 336–37 (1997) (asserting that an individual’s genetically determined behavioral
traits may play a major role in questions of character evidence at trial and that genetic
“character evidence” would differ from traditional character evidence by virtue of its
permanency).
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icant in the civil context.  In comparing the two damage hypotheticals
(Hypotheticals #5 and #6), the judges were much more hesitant to
compel a test at the request of the defendant for purposes of mitigating
damages than to admit a test result at the request of a plaintiff to ex-
pand damages.  We speculate that this was more likely due to con-
cerns about the psychological trauma of an unwanted predictive test
revealing a gene for a terminal, incurable disease than concerns about
compelling a test for purposes of determining damages per se. In Hy-
potheticals #3 and #4, the large majority of judges had no trouble
compelling a test to prove or refute negligence as the cause of the
plaintiff’s injury, presumably because the plaintiff could terminate the
case.  The same would be true in the context of damages, i.e., the
plaintiff could withdraw from the case.  The posture of the case, how-
ever, may also be important to judicial evaluation.  If the hypothetical
we posed in the causation context involved testing for a condition that
was lethal and could lead to childhood death, it is not clear whether
the judges would have been less willing to compel the test as the infor-
mation was potentially relevant to the defendant’s liability.  However,
if in that same case, the defendant wished to compel a genetic test in
the damages portion of the case, judges may have been more reluc-
tant to compel the test both because of the psychological conse-
quences and because it could be considered unfair to shortchange a
plaintiff who happens to have a genetic condition that will lead to his
early death.  Moreover, judges may believe it would be worse to
“force” withdrawal in the damages phase by a plaintiff who has already
established liability than to force one to withdraw before he has estab-
lished any wrong.
If both Hypotheticals #5 and #6 had been requests to admit a ge-
netic test result, we predict that the difference in judicial responses
between the two hypotheticals would not have been as great, but that
the judges still would have been less likely to admit the NF-2 test re-
sult.  Even if the plaintiff in Hypothetical #5 had already had a genetic
test indicating that he had the gene mutation for NF-2 and was aware
of the result, judges might have been more reluctant to admit the test
for the reasons stated above, i.e., it seems unjust to reduce the plain-
tiff’s damages because he got an unlucky number in the genetic lot-
tery of life.112  Some might consider this reduction of damages a
112. Courts in prior cases have split on whether to compel and/or admit HIV tests for
the purpose of determining life expectancy in civil cases. Compare Sacramona v. Bridge-
stone/Firestone Inc., 152 F.R.D. 428, 431 (D. Mass. 1993) (refusing to compel a personal
injury plaintiff to undergo HIV testing because the plaintiff did not place his life expec-
tancy “in controversy” under the Federal Rules of Civil Procedure by seeking future dam-
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“windfall” for a negligent defendant, especially if the damages would
have been larger if the plaintiff did not have the genetic condition.
This latter argument is supported by the principle of retributive
justice—the belief that defendants should be sanctioned for their
wrongdoing.  Moreover, it assumes that defendants who are equally at
fault should be liable for similar amounts of damages and that those
tortfeasors who are “lucky enough” to encounter a plaintiff with a
shorter life expectancy should not benefit from their victim’s misfor-
tune.  The argument is further bolstered by economic/instrumental
claims that deterrence is a legitimate goal of tort law that should not
be undermined by schemes focusing solely on compensation.113  Ac-
cording to this perspective, damages should be sufficient to en-
courage potential wrongdoers to minimize risks, i.e., take “cost-
justified precautions.”114
B. Legal Purpose of the Test
A second factor that must be considered in analyzing a request to
admit or compel a genetic test is the purpose for which the test infor-
ages), and Doe v. Roe, 526 N.Y.S.2d 718, 726–27 (N.Y. Sup. Ct. 1988) (stating, in the
context of a custody battle, that a father’s potentially shortened life span does not rise to
the level of a “compelling need” sufficient to order involuntary HIV testing), with Agosto v.
Trusswal Sys., 142 F.R.D. 118, 120 (E.D. Pa. 1992) (admitting plaintiff’s positive HIV status,
upon finding that he waived his privilege to confidentiality when he sought compensation
for future pain and suffering and lost wages in a products liability suit), and Pettyjohn v.
Goodyear Tire & Rubber Co., Civ. A. No. 91-CV-2681, 1992 WL 105162, *1 (E.D. Pa. Apr.
29, 1992) (granting defendant’s motion to compel plaintiff to submit to HIV testing in a
personal injury case, where defendant’s purpose for the discovery request was to establish
plaintiff’s reduced life expectancy); see also Niedwiecki, supra note 16, at 320–26 (discussing R
cases of court-ordered HIV testing); Ugo Colella, HIV-Related Information and the Tension
Between Confidentiality and Liberal Discovery: The Need for a Uniform Approach, 16 J. LEGAL MED.
33, 35 (1995) (discussing civil discovery disputes involving HIV-related information).
Courts may distinguish situations where the disease or condition is immutable from those
where the condition is due to lifestyle or behavior, e.g., smoking or drug use. See, e.g.,
Wehmeier v. UNR Indus. Inc., 572 N.E.2d 320, 340 (Ill. App. Ct. 1991) (“ We conclude the
smoking evidence was relevant to the issues of causation and damages and should have
been admitted on these issues without restriction. ”); Rawlings v. Andersen, 240 N.W.2d
568, 573 (Neb. 1976) (“In an action where permanent, personal injury is claimed, the
defendant may show as affecting damages that the plaintiff was a person of intemperate
habits.”).
113. See JULES L. COLEMAN, RISKS AND WRONGS 237–39 (1992) (discussing the economic
theory of deterrence); Michael L. Rustad & Thomas H. Koenig, Taming the Tort Monster:
The American Civil Justice System as a Battleground of Social Theory, 68 BROOK. L. REV. 1, 56
(2002) (analyzing the underlying policy reasons for civil damage awards); Benjamin C.
Zipursky, Symposium, Civil Recourse, Not Corrective Justice, 91 GEO. L.J. 695 (2003) (discuss-
ing and critiquing the corrective justice theory).
114. See COLEMAN, supra note 113, at 238–39 (suggesting that liability rules should en- R
courage “cost-justified precautions”).
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mation will be used.  Whether the information will be used to deter-
mine guilt or innocence, liability, causation, damages, or sentencing
will have different implications for judicial decisionmaking.
Thus far, the most frequent use of health-related genetic tests in
the courtroom has been in the context of establishing or refuting cau-
sation.  While in the medical malpractice context the use of genetic
test results may be appropriate to show that a defendant’s negligence
was not the cause or sole cause of a plaintiff’s injuries, the use of ge-
netic test results in toxic tort litigation to establish or exclude a ge-
netic cause for the plaintiff’s condition can be problematic due to the
uncertainties of proof of causation in toxic injury claims.
Defendants have attempted to use genetic tests to show either
that the plaintiff has a genetic condition that accounts for her dis-
ease/disability or that the plaintiff had a genetic susceptibility to a
disease/disability that made it more likely than not that the disease
would have occurred without the toxic exposure.115  Plaintiffs have
tried to refute these arguments by showing that they either do not
have a genetic condition or predisposition to a genetic disease or that
exposure to a toxic substance caused their disease/disability because
of their genetic susceptibility or sensitivity to the substance.116
Genetic tests may be valuable to defendants who wish to show
that the plaintiff’s condition is due to a genetic anomaly or susceptibil-
ity, and not toxic exposure, e.g., Fragile X syndrome versus lead paint.
In such cases, the gene may explain all of the plaintiff’s disabilities.
However, it is also possible that both the genetic condition and the
lead exposure could contribute to the plaintiff’s symptoms.
In cases where the defendant wishes to show that the plaintiff had
a “disease susceptibility gene,” the use of a genetic test is more troub-
lesome, especially if the test is being used in an attempt to rule out the
toxic exposure as a cause of the plaintiff’s infirmities.  This is because
of the different ways in which genetic variations may increase disease
susceptibility.  They may “facilitate toxic injury by making an affected
cell more or less susceptible to toxic insult,” or alternatively, “they may
115. Poulter, supra note 16, at 212–13 (discussing the impact of genetic testing on a R
plaintiff’s proof of causation in toxic tort cases).
116. In In re Hanford Nuclear Reservation Litig., No. CY-91-3015-AAM, 1998 WL 775340, at
*64–65 (E.D. Wash. Aug. 21, 1998), rev’d on other grounds, 292 F.3d 1124, 1139 (9th Cir.
2002), plaintiffs argued that they developed thyroid cancer from radiation exposure be-
cause they had a genetic sensitivity to such exposure.  The argument was unsuccessful as
they were unable to find reasonable scientific support for individual susceptibility. Id. at
*67.
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be involved in independent disease etiologies that do not involve the
toxic insult at issue.”117  According to Poulter:
The “alternative cause” model posited by many commenta-
tors is valid only if the second mode of action applies, [i.e.,
the plaintiff had a genetic predisposition to the disease at
issue and likely would have developed the disease indepen-
dently of the exposure to the toxic substance] yet the first
mode is more consistent with current understandings of
many diseases with genetic components.  When it is not
known whether the genetic variation facilitates toxic injury
or is involved in an independent disease pathway, genetic
testing will not assist causal analysis.118
Where the first mode of action applies, the disease is a result of
both the genetic susceptibility and the toxic exposure.  Attempting to
determine whether the toxic exposure legally caused the plaintiff’s
disease or condition where the disease is a result of multiple causes is
fraught with difficulties.  We avoided these complexities in Hypotheti-
cal #4 by making it clear that the condition at issue only resulted when
both the genetic susceptibility and the toxic exposure existed.  In most
cases, however, the mechanism of causation will not be known.  More
specifically, we will not know whether: (1) the disease was a result of
the genetic susceptibility alone or the toxic exposure alone; (2) the
toxic exposure triggered the genetic susceptibility; or (3) the toxic
exposure accelerated the disease manifestation so that it occurred ear-
lier than it might have otherwise.  If the disease is a result of both a
genetic susceptibility and a toxic insult, we will not know whether the
interaction between the two causes is additive, synergistic, or antago-
nistic.119  Poulter argues that in cases where we do not yet understand
the actual disease mechanism, courts should not permit the introduc-
tion of genetic test results in toxic tort cases.120
Despite the mechanistic complexities,121 some authors have spec-
ulated as to how genetic test results indicating genetic susceptibility to
117. Poulter, supra note 16, at 213. R
118. Id. at 213.  Even if the second mode of action applies, this does not rule out the
possibility that the toxic exposure had a harmful effect on the plaintiff. Id. at 219–20.
119. See id. at 222, 230.
120. Id. at 236 (“Where information about the relationship between genetic susceptibil-
ity and toxic insult is not understood, genetic testing will not be probative.”).
121. In addition to the complexities identified by Poulter, Marchant explains:
Even when a susceptibility genetic marker has been unambiguously identified, its
effects can vary across individuals for a variety of reasons.  Some increases in sus-
ceptibility are dose-dependent, in that they primarily increase an individual’s sus-
ceptibility to a toxic agent relative to the general population only at low or high
doses.  Certain associations appear to be ethnic-dependent, in that the susceptibil-
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a toxic substance may affect causation determinations in litigation.
Such cases are subject to the same difficulties as are present in other
toxic tort cases.122 Plaintiffs, as an initial matter, will need to show that
the toxic exposure was “more likely than not” the cause of the plain-
tiff’s disease or condition.123  Often, under current tort doctrine, in
order to satisfy the “more likely than not standard” courts require that
plaintiffs show that the relative risk of the disease at issue as a result of
exposure to the toxic substance is greater than two.  This is often a
difficult hurdle for plaintiffs;124 however, plaintiffs who can show that
they have a genetic susceptibility to disease based on exposure to the
toxic substance may be able to surmount the causation hurdle.125
If causation can be established, the fact that someone has a ge-
netic predisposition to disease based on toxic exposure would gener-
ally not reduce damages in a case alleging that exposure to a toxic
ity associated with a particular gene appears to be limited to particular ethnic
groups and is not seen in other groups even when the same gene is present. . . .
Finally, individual susceptibility to potentially toxic agents is rarely determined by
a single genetic locus, but rather is the combined influence of many different
genes (as well as non-genetic factors).
Gary E. Marchant, Genetics and Toxic Torts, 31 SETON HALL L. REV. 949, 952–53 (2001).
122. See generally Ellinger, supra note 16 (discussing the legal implications of using DNA R
diagnostic technology in toxic tort litigation); Susan R. Poulter, Science and Toxic Torts: Is
There a Rational Solution to the Problem of Causation?, 7 HIGH TECH. L.J. 189 (1992) (discuss-
ing the challenges of proving causation in cases of toxic torts); see also Marchant, supra note
16, at 89 (“One of the most formidable obstacles that injured plaintiffs face in toxic injury R
litigation is to demonstrate that the defendant’s product or action caused the plaintiff’s
injuries.”); Mark Parascandola, What Is Wrong with the Probability of Causation?, 39
JURIMETRICS 29, 29–30 (1998) (arguing that causation is difficult to prove in toxic tort cases
because “the injury in question is typically a chronic disease that may develop years later
following long-term exposure to low doses of a carcinogen or other toxin . . . [and] the
mechanism by which the toxin causes the disease may be poorly understood”).
123. See Poulter, supra note 16, at 217. R
124. A number of statistical experts have argued that this standard is flawed and unfairly
disadvantages plaintiffs. E.g., Sander Greenland & James M. Robins, Epidemiology, Justice,
and the Probability of Causation, 40 JURIMETRICS 321, 331–33 (2000); Mark Parascandola,
supra note 122, at 37–39.  Some have argued that in cases where plaintiffs cannot meet the R
“more likely than not” rule, plaintiffs should receive partial compensation based on the
cause that is attributable to the defendant’s actions.  This has been referred to as “propor-
tional recovery.” See Poulter, supra note 16, at 224 & n.63 (citing In re Agent Orange Prod- R
uct Liab. Litig., 597 F. Supp. 740 (E.D.N.Y. 1984), aff’d, 818 F.2d 145 (2d Cir. 1987), cert.
denied, Pinckney v. Dow Chem. Co., 484 U.S. 1004 (1988)).
125. See Marchant, supra note 16, at 67–68 (noting that a plaintiff could satisfy the more R
probable than not standard if she has a genetic susceptibility to cancer from exposure to
defendant’s product); see also Marchant, supra note 121, at 954–56 (discussing cases in R
which plaintiffs made a genetic susceptibility argument).  While in some circumstances
such tests may assist plaintiffs, in others, defendants may use genetic tests to show that
plaintiffs have a gene that makes them more resilient or resistant to toxic exposures than
the average person, therefore reducing the likelihood that the toxic exposure in question
caused the plaintiff’s harm. Id. at 956.
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chemical caused the harm.  As indicated by a number of judges who
participated in our survey, in these cases the court would likely adopt
the well-known tort doctrine that a tortfeasor takes her victim as she
finds him—the fact that an individual is highly sensitive to a chemical
exposure is not particularly helpful to the defendant.  Where the
plaintiff had a pre-existing physical condition, the defendant is liable
for the full extent of the plaintiff’s harms even if the defendant could
not have foreseen such harms.126
While the majority of courts may apply this rule, in the context of
product liability cases, some courts have accepted a defendant’s argu-
ment that its product was not “defective or unreasonably dangerous” if
the plaintiff had a rare, idiosyncratic and unforeseeable reaction to
the product.127  Conceivably, some courts might apply this “idiosyn-
cratic response defense” in cases of a rare genetic condition.128  While
the rule may be appropriate in cases where the causal link between
the product and the genetic condition had not been established, once
evidence of such a relationship exists, manufacturers should be re-
quired to warn individuals with the genetic sensitivity of the risk.129
126. See, e.g., Dahlen v. Gulf Crews, Inc., 281 F.3d 487, 495 (5th Cir. 2002) (citing in
support of this rule RESTATEMENT (SECOND) OF TORTS § 461 (1965)); Tuite v. Stop & Shop
Cos., 696 A.2d 363, 367 (Conn. App. Ct. 1997) (same); Cavens v. Zaberdac, 849 N.E.2d
526, 530 (Ind. 2006) (same); Benn v. Thomas, 512 N.W.2d 537, 539–40 (Iowa 1994)
(same); Wilkinson v. Lee, 617 N.W.2d 305, 309 (Mich. 2000) (same); see also RESTATEMENT
(THIRD) OF TORTS: LIABILITY FOR PHYSICAL HARM § 31 (Proposed Final Draft No. 1, 2005);
W. PAGE KEETON ET AL., PROSSER AND KEETON ON THE LAW OF TORTS § 43, at 290–93 (W.
Page Keeton ed., 5th ed. 1984) (commenting on liability beyond the risk a defendant rea-
sonably anticipated).
127. Marchant, supra note 16, at 79–81; see also RESTATEMENT (THIRD) OF TORTS: PROD- R
UCTS LIABILITY § 2 cmt. k (1998) (noting that products do not have to contain warnings of
risks of allergic reactions that are not reasonably foreseeable at the time of sale); Daley v.
McNeil Consumer Prods. Co., 164 F. Supp. 2d 367, 373 (S.D.N.Y. 2001) (“The supplier
owes no special duty of warning to the unknown few who constitute a mere microscopic
fraction of potential users who may suffer some allergic reaction not common to the ordi-
nary or normal person.” (internal quotation marks omitted)).  Evidence of linkages be-
tween genes and allergic reaction has surfaced in a variety of cases. See, e.g., Roberto
Littera et al., HLA-Dependent Hypersensitivity to Nevirapine in Sardinian HIV Patients, 20 AIDS
1621, 1621 (2006) (documenting a link between allergic reactions to an AIDS medication
and a gene more prevalent in Sardinians than other Italians).
128. Marchant, supra note 16, at 80–81 & n.73.  Marchant notes that the idiosyncratic R
response defense “applies when the product would not be expected to cause similar health
effects in a ‘normal’ or ‘average’ person.  The formal justification for this defense is that
the hyper-susceptibility of the plaintiff, rather than the product, is the proximate cause of
the plaintiff’s injury.” Id. at 80 (footnotes omitted).
129. In fact, where courts have applied an idiosyncratic response defense, some have
based the defense on “the unforeseeability of the rare susceptibility in the exposed popula-
tion.”  Marchant, supra note 16, at 81.  In general, these courts have held that “a ‘normally R
safe’ product that injures only a small number of susceptible individuals is not defective,
but must be accompanied by a warning when the manufacturer knew or should have
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The question of whether this latter doctrine will apply to cases
where a product harms an individual with a genetic susceptibility has
yet to be resolved.  However, it raises the question as to where, in
these cases, the burden should fall—on the innocent victim or the
product manufacturer.  Beyond this broader policy question, the ap-
plication of the doctrine will require some articulation as to how rare
the genetic condition would have to be before it would attach.130
An additional use of genetic tests in the context of determining
causation has been proposed where a plaintiff has a unique physiolog-
ical or cellular abnormality that is attributable to exposure to a spe-
cific toxin, i.e., a biomarker.  As has been seen in some benzene
exposure cases, defendants may attempt to disprove causation by argu-
ing that the plaintiff’s blood or tissue sample did not display the “cor-
rect” type of cellular damage.131  Judges should be wary of these types
of arguments, however, because it is often difficult for laypersons to
distinguish between valid scientific bases for the claims and more ten-
uous ones.132  For example, the theory of a chromosome-specific
known of the potential for an idiosyncratic response, no matter how unusual.” Id.  Other
courts, however, have emphasized “the undue burdens that liability would impose for a
product that is safe for most people” and have held that there is “no defect or duty to warn,
even when the defendant knows or should know that there are likely to be a small number
of unidentifiable susceptible individuals.” Id. at 81–82.
130. See RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 2 cmt. k (stating a gen-
eral rule, followed by the majority of courts, for required warnings on products in cases
involving allergic or idiosyncratic reactions to products).  Generally, “a warning is required
when the harm-causing ingredient is one to which a substantial number of persons are
allergic” and “[t]he ingredient that causes the allergic reaction must be one whose danger
or whose presence in the product is not generally known to customers.” Id.  In most cases,
a plaintiff must show that “the allergic predisposition is not unique to the plaintiff”; how-
ever, the court may also consider “the severity of the plaintiff’s harm.” Id.  In addition,
warnings need not be provided for risks of allergic reactions that are not reasonably fore-
seeable at the time of sale. Id.; see also Mountain v. Procter & Gamble Co., 312 F. Supp. 534
(E.D. Wis. 1970) (holding that manufacturers of a shampoo owed no duty to warn of possi-
ble allergic reactions to the product when only a slight percentage of total sales resulted in
injury); Morris v. Pathmark Corp., 592 A.2d 331 (Pa. Super. Ct. 1991) (holding that the
manufacturer was not liable and a warning was not required on a product that caused the
plaintiff to manifest an unusual or rare idiosyncratic sensitivity because there was “no evi-
dence that the product had contained an ingredient to which a significant number of
persons were allergic”). But see Gober v. Revlon, Inc., 317 F.2d 47 (4th Cir. 1963) (holding
that whether manufacturers of nail polish owed a duty to warn even though the number of
users injured by the polish was small was a proper question for the jury).
131. See supra note 23 and accompanying text. R
132. See, e.g., Samuel H. Wilson & William A. Suk, Overview and Future of Molecular Bi-
omarkers of Exposure and Early Disease in Environmental Health, in BIOMARKERS OF ENVIRONMEN-
TALLY ASSOCIATED DISEASE 3, 9 (Samuel H. Wilson & William A. Suk eds., 2002) (“[I]n a
broad sense, it is fair to say that the promise of biomarkers has not yet moved from the lab
to the clinic or from development to application.”).  According to Suk and Wilson, “pro-
pos[als] to develop biomarkers using assays that detect DNA strand breaks, chromosomal
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“benzene fingerprint” is not widely accepted, whereas a number of
protein biomarkers for benzene exposure have been validated.133
In the criminal context, whether the genetic test information will
be used for a determination of guilt or in sentencing does, and argua-
bly should, make a difference in how judges evaluate whether to admit
or compel the test.  As discussed above, genetic tests for use in the
guilt or innocence phase of a criminal proceeding raise both Fourth
and Fifth Amendment issues.134  The overlay of Fourth Amendment
protections, however, may be of less concern in the sentencing pro-
cess than in the conviction phase of a criminal proceeding because
courts have fairly consistently referred to the felon’s lower expectation
of privacy, especially as it pertains to issues of incarceration.135  In the
sentencing phase, judicial evaluation of requests to admit or compel a
genetic test may depend on who is making the request.  Conceivably
either side could make the request, but for opposite reasons—the de-
fendant may argue that he should have a reduced sentence, as his
genetic trait prevented him from exercising free will; in contrast, the
prosecution may seek a harsher sentence, claiming the defendant is
dangerous and incurable.136
aberrations, micronuclei, or the endogenous rate of DNA repair or mutation . . . are
suboptimal for biomarker development, largely because of unresolved issues in their repro-
ducibility, accuracy, validation and interpretation.” Id. at 10.
133. See, e.g., Matthew S. Forrest et al., Discovery of Novel Biomarkers by Microarray Analysis of
Peripheral Blood Mononuclear Cell Gene Expression in Benzene-Exposed Workers, 113 ENVTL.
HEALTH PERSP. 801, 804–05 (2005), available at http://www.pubmedcentral.nih.gov/ar-
ticlerender.fcgi?artid=1257610 (identifying four genes that show altered expressions after
high occupational exposure to benzene); Roel Vermeulen et al., Decreased Levels of CXC-
Chemokines in Serum of Benzene-Exposed Workers Identified by Array-Based Proteomics, 102 PNAS
17041, 17046 (2005), available at http://www.pnas.org/cgi/content/full/102/47/17041
(finding decreased levels of a circulating protein could be a potential biomarker of the
early stage biological effects of benzene).
134. See supra notes 64–89 and accompanying text. R
135. See, e.g., Hudson v. Palmer, 468 U.S. 517, 527–28 (1984) (“A [Fourth Amendment]
right of privacy . . . is fundamentally incompatible with the close and continual surveillance
of inmates and their cells required to ensure institutional security and internal order . . . [,
and] the prisoner’s expectation of privacy always yield[s] to what must be considered the
paramount interest in institutional security.” (footnotes omitted)); see also Groceman v.
U.S. Dep’t of Justice, 354 F.3d 411, 413–14 (5th Cir. 2004) (per curiam) (pointing out that
an incarcerated individual has a lower expectation of privacy); United States v. Kincade,
379 F.3d 813 (9th Cir. 2004) (holding that application of “a totality of the circumstances
analysis to uphold compulsory DNA profiling of convicted offenders” comports with the
Fourth Amendment and Supreme Court precedent); Vore v. U.S. Dep’t of Justice, 281 F.
Supp. 2d 1129, 1133, 1137 (D. Ariz. 2003) (upholding the constitutionality of a DNA col-
lection statute and remarking on the Ninth Circuit’s statement that the Supreme Court in
Hudson “may have intended to strip the inmates of all Fourth Amendment privacy rights”
(quoting Somers v. Thurman, 109 F.3d 614, 617 (9th Cir. 1997))).
136. See Denno, supra note 16, at 254 (describing the potential use of genetic evidence R
as a “double-edged sword”).
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C. Concerns about Genetic Tests Related to Health and Behavior
Judges will need to consider a third set of factors when evaluating
requests to admit genetic test results or compel genetic tests.  These
factors, which relate to the unique features of health- and behavior-
related genetic tests and conditions, include: the scientific value or
utility of the test; the nature of the genetic trait or condition; the psy-
chological impact of the tests, their impact on personal privacy, and
on the privacy of relatives of the person tested; concerns about ge-
netic determinism; and the use of a pre-existing technology for a new
purpose.
1. Test’s Scientific Value and Nature of Genetic Trait or Condition
The multiple factors that form the decision matrix in Figure 1 go
beyond the challenging Daubert and Frye questions that will be raised
by these tests.  These factors provoke additional questions about ad-
missibility, i.e., is a test result admissible if it indicates that an individ-
ual has a gene that only has a 40-60% probability of expression?  What
is the test’s utility?  While both genetic and non-genetic tests can be
used for diagnostic and predictive purposes, genetic tests for certain
diseases provide more definitive diagnoses than other non-genetic,
medical tests and can “identify predispositions that are exclusively
transmitted . . . from parent to child.”137  However, the predictive abil-
ity of the tests varies greatly, depending on the gene being analyzed
and the data linking that gene to a future disease risk.138
In the courtroom, genetic tests could be used to support a diag-
nosis, especially when clinical experts disagree over whether the indi-
vidual has the condition.  Yet, not all genetic tests would be equally
valuable for this purpose.  A genetic test will only reveal whether
someone has the gene or mutation for a genetic condition; it does not
indicate whether the individual has the condition unless the gene is
100% penetrant, i.e., there is a 100% correlation between having the
gene mutation and having the disease or condition and the condition
has an early onset.  Thus, the value of the test depends on its predic-
tive ability (which is dependent on gene penetrance) and the age of
onset of the genetic condition.  A third factor that must also be con-
sidered is the variability of expression of the symptoms of the genetic
137. Michael J. Green & Jeffrey R. Botkin, “Genetic Exceptionalism” in Medicine: Clarifying
the Differences Between Genetic and Nongenetic Tests, 138 ANNALS INTERNAL MED. 571, 572
(2003), available at http://www.annals.org/cgi/content/abstract/138/7/571.
138. See generally DOROTHY NELKIN & LAURENCE TANCREDI, DANGEROUS DIAGNOSTICS (2d
ed. 1994) (discussing the potential uses and abuses of genetic tests, as well as problems of
reliability associated with the tests).
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disease or illness, i.e., whether it is a mild or severe case.  Different
expression levels can arise as a result of environmental factors that
alter cellular processes or because other genes and their protein prod-
ucts often exert a modifying effect on gene expression.139
Penetrance may, in part, relate to whether the genetic condition
at issue is monogenic (i.e., the result of a single gene mutation)140 or
multifactorial (i.e., the result of a combination of multiple genes or
both genetic and environmental factors).141  A monogenic disease
may be present at birth or be “late onset.”  In the latter situation, it is
highly likely that the genetic condition will manifest as long as the
individual lives long enough, notwithstanding environmental factors.
Genetic tests for monogenic disorders are generally more reliable
than those for complex, multifactorial diseases because tests for com-
plex disorders currently do not include information on the
probability that an individual with a mutation associated with a disease
actually will develop that disease.142
In response to the hypotheticals that we included in our survey,
judges were much more willing to admit a test result or compel a test
when it was for a gene that was highly penetrant.  For example, in the
medical malpractice case (Hypothetical #3) where the genetic test was
being requested to confirm a diagnosis of Fragile X, a condition for
139. See Leena Peltonen & Victor A. McKusick, Genomics and Medicine: Dissecting Human
Disease in the Postgenomic Era, 291 SCI. 1224 (2001), available at http://www.sciencemag.org/
cgi/content/full/291/5507/1224 (discussing individual variations in genetic diseases re-
sulting from the modifying effects of other genes, the environment, or an individual’s life-
style choices).
140. Monogenic disorders include Huntington’s disease, cystic fibrosis, Tay-Sachs dis-
ease, sickle cell anemia, hemophilia, Fragile X syndrome, thalassemia, and hereditary
hemochromatosis, among others.
141. The influence of “nature v. nurture” has long been debated in relation to many
illnesses. See, e.g., Norman Poythress et al., Scientific Status, in SCIENCE IN THE LAW 22, 29
(David L. Faigman et al. eds., 2002) (“Although there is general consensus that genetics is
a significant etiological factor in the major psychoses, debate remains concerning the role
of the environment. . . .  [P]eople vary widely in their responses to adverse life events, and
the interaction of stress with underlying psychological (subjective) or biological factors is
poorly understood.”).
142. See, e.g., Lori Andrews & Erin Shaughnessy Zuiker, Ethical, Legal, and Social Issues in
Genetic Testing for Complex Genetic Diseases, 37 VAL. U. L. REV. 793, 803–05 (2003) (explain-
ing the reduced predictive value of genetic tests for complex diseases).  Providing good
reason for why genetic tests for complex disorders are less reliable, David Bentley explains
that “we fall short at present . . . in our understanding of physiological function or how sets
of molecules work together, and in our ability to infer this from the accumulated informa-
tion linked to the genome.”  David R. Bentley, Genomes for Medicine, 429 NATURE 440, 441
(2004).  Bentley points out that geneticists currently do not understand “the functional
sequences outside genes, . . . when and where genes are expressed, and in response to what
signals” or “the biochemical functions of most proteins, and . . . most of the interactions
between cellular components.” Id.
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which virtually 100% of individuals with the genetic mutation have the
condition at birth, the large majority of judges were willing to compel
the test.  In contrast, in the first criminal hypothetical (Hypothetical
#1) where the plaintiff wished to admit a genetic test to support a
diagnosis of schizophrenia, arguably, the judges were less comfortable
admitting the test because the gene penetrance was only 50–60%.
Where the purpose of the test was to aid the judges in prognosti-
cation, as in the hypotheticals involving criminal sentencing (Hypo-
thetical #2) and determination of life expectancy (Hypothetical #5),
the judges were much less willing to compel the test.  Such hesitancy
appeared due to concerns about gene penetrance as well as gene ex-
pression.  In the criminal case (Hypothetical #2), the penetrance of
the gene again was only 50–60%.  In the civil damages case (Hypothet-
ical #5), while the penetrance of the gene was very high, there was
significant variability in the severity of symptoms an individual with
the gene would manifest.  Such variability also may have accounted for
judicial reluctance to admit the test result in that scenario.
2. Psychosocial Issues (Privacy, Stigma, Psychological Harms)
Judicial reluctance to compel or admit genetic tests was also tied
to concerns about stigma, privacy, and the psychological impact of re-
ceiving unwanted information about a lethal and incurable genetic
condition.  Judges were sensitive to situations where news of a genetic
condition could be psychologically devastating, as when there is no
cure or treatment for it.  Academics who have written on this issue
have also expressed concerns about this element of health-related ge-
netic testing.  As one author put it, “[m]any DNA tests have the poten-
tial to reveal not only information of direct relevance to the litigation,
but additional information of profoundly disturbing personal signifi-
cance, information that may be only peripherally related or even un-
related to the physical harm that has been placed at issue in
litigation.”143
In addition to psychological harms, the disclosure of such infor-
mation may also carry “relational harms.”  Studies have demonstrated
that potential spouses may be discouraged from entering a marriage
143. Ellinger, supra note 16, at 33.  Ellinger provides the example of Huntington’s Dis- R
ease (HD), for which “[a] DNA diagnostic test . . . can inform presymptomatic at-risk indi-
viduals whether they will almost certainly develop HD,” and cites one study finding that
“over two-thirds of at-risk persons expected they would become depressed if DNA tests
were positive, and another study [showing] that twenty-one percent of at-risk individuals
might commit suicide if the tests were positive.” Id. at 68 (footnote omitted).
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with a person carrying a “disease gene,” while current spousal relation-
ships may also be negatively affected by such revelations.144
The hypotheticals included in our survey highlight issues that
may arise when the genetic test relates to mental and behavioral traits
as well as physical health.  The former may have given judges signifi-
cantly greater pause.  Such hesitation is warranted in light of the
stigma associated with behavioral traits like aggression and impulsive-
ness as well as the role of genetics in such behaviors.  Rothenberg and
Wang confirm these reasons for caution, asserting that “[a]s one
moves toward the behavioral end of the spectrum, the genetic influ-
ence on a trait becomes more uncertain and difficult to isolate, while
the stigma associated with such influence becomes more signifi-
cant.”145  These concerns are clearly more weighty in the context of
compelling a test than admitting an existing test result, since a litigant
who seeks to admit a test has (presumably) decided that the value of
the knowledge one gains from the test outweighs the potential harm
(to oneself, at least), while a request to compel seeks to deny the indi-
vidual who is to be tested the opportunity to strike that balance.
Moreover, genetic information can have a devastating impact on
blood relatives who may be at risk for developing a genetic disease,
but do not wish to know that they are at risk for such a condition.146
These third parties, who likely have no role in the legal proceeding, by
144. See Andrews & Zuiker, supra note 142, at 811–12 (citing primary research that R
found 5% of female and 31% of male carriers of the Tay-Sachs recessive mutation were
likely to change marriage plans if their intended spouse was also a carrier, as well as results
indicating nearly one-third of couples divorced following positive testing of one spouse for
the dominant Huntington’s mutation).
145. Karen Rothenberg & Alice Wang, The Scarlet Gene: Behavioral Genetics, Criminal Law,
and Racial and Ethnic Stigma, 69 LAW & CONTEMP. PROBS. 343, 353 (2006).  Rothenberg and
Wang further assert that while behavioral traits are the most “indeterminate and controver-
sial subjects of genetics research,” they also “may be the most relevant to criminal law”
where conditions that contribute to violence, such as alcoholism, mental illness and antiso-
cial behavioral traits, may assist prosecutors and judges in conviction and sentencing. Id. at
354; see also generally TED PETERS, PLAYING GOD?: GENETIC DETERMINISM AND HUMAN FREE-
DOM (1997) (discussing ethical challenges to moral responsibility when genes predispose
individuals to criminal behavior).
146. See, e.g., Green & Botkin, supra note 137, at 572 (“Another feature of predictive R
genetic testing is that results can affect a patient’s family.”); C. Christopher Hook et al.,
Primer on Medical Genomics Part XIII: Ethical and Regulatory Issues, 79 MAYO CLINIC PROC. 645,
646 (2004) (raising the issue of whether patients should have the right not to know about
the presence of genetic diseases, particularly about late-onset disorders); Samuel C. Seiden
& Karine Morin, The Physician as Gatekeeper to the Use of Genetic Information in the Criminal
Justice System, 30 J.L. MED. & ETHICS 88, 89 (2002) (maintaining that genetic test results
deserve a higher standard of confidentiality because they might reveal information about a
patient’s family members and their risks for developing a genetic disease, and that such
information may be unknown to those family members).
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virtue of their genetic relationship, may be “victims” harmed psycho-
logically and in other ways by the revelation of this “unwanted”
information.147
A few authors have discussed the value of protective orders to
preserve individual privacy in civil cases where genetic tests are com-
pelled or admitted.  Rothstein asserts that such orders should be is-
sued when defendants are seeking to discover plaintiffs’ genetic
profiles in an attempt to limit their financial liability.148  Others have
argued that issuing protective orders is not an adequate remedy for
the invasion of privacy imposed by court-ordered genetic testing be-
cause individuals would be unable to keep the information private
when, for example, applying for health insurance or employment.149
3. Genetic Determinism
Concerns about genetic determinism, i.e., “the impulse to treat
DNA as destiny, discounting the possibility of deviating from one’s ge-
netic predisposition,”150 appeared more important in the criminal
than in the civil context where “branding” has the potential to deprive
an individual of liberty.  This was evident in the hypothetical use of a
genetic test to determine “future dangerousness” in a sentencing pro-
ceeding (Hypothetical #2).  Judges may have been concerned about
such use because it may overemphasize the influence of genes on
human behavior.  Rothenberg has termed this overemphasis “genetic
myopia”;151 others have referred to it as “genetic essentialism.”152
The problem with over reliance on genetics is that it shifts the
blame for the undesirable behavior from individual free will and the
influence of family and environment to a person’s hardwiring.  Use of
genetic test results to show that the defendant lacked the requisite
147. For example, if a sister of a woman who discovers that she has a genetic predisposi-
tion to ovarian cancer finds out this information, she would know that she is also at an
increased risk of having a similar genetic predisposition.  The sister may not wish to know
this information.  Or, a child of a man who discovers that he has the gene for Huntington’s
Disease may not want to know this fact given that the child will then have a fifty percent
probability of having the disease.
148. Rothstein, Preventing the Discovery, supra note 24, at 879, 901–02.  Rothstein pro- R
poses this judicial approach as one of “three alternatives designed to promote the plain-
tiff’s interests in privacy and confidentiality, the defendant’s interest in avoiding
overcompensation, the judiciary’s interest in avoiding complexity in litigation, and the
public’s interest in the public health and the conservation of health resources.” Id. at 879.
149. Niedwiecki, supra note 16, at 345. R
150. Rothenberg & Wang, supra note 145, at 356. R
151. Karen H. Rothenberg, Breast Cancer, the Genetic “Quick Fix,” and the Jewish Community:
Ethical, Legal, and Social Challenges, 7 HEALTH MATRIX 97, 102 (1997).
152. E.g., Rochelle Cooper Dreyfuss & Dorothy Nelkin, The Jurisprudence of Genetics, 45
VAND. L. REV. 313, 320–21 (1992).
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mens rea or to predict future dangerousness invokes concerns about
genetic determinism and illuminates the tension underlying ongoing
debates about free will and theories of punishment.  The instrumen-
talist goals of deterrence and incapacity could be used to argue that
because the defendant has a genetic predisposition to violence, he
cannot be “cured” or deterred and thus he requires a longer period of
incarceration.  The goal of retribution for voluntary immorality would
lead to an argument that the defendant does not deserve the full ex-
tent of punishment because he is not fully culpable for the crime.153
The concern about genetic determinism is consistent with a
larger uneasiness in the relationship between law and the sciences and
is at the crux, for example, of disagreements about the insanity de-
fense and the legal doctrine of diminished capacity.  Michael Perlin
articulates the tension as it plays out in the insanity defense, stating:
The insanity defense symbolizes the gap between the as-
pirations of a theoretically positivist, objective, common law
legal system (in which behavior is allegedly animated by free
will and is judged and assessed on a conscious level), and the
reality of an indeterminate, subjective, psychosocial universe
(in which behavior is determined by a host of biological, psy-
chological, physiological, environmental and sociological
factors, and is frequently driven by unconscious forces).154
Genetic determinism emphasizes the biological component of this ad-
mixture of forces, potentially ignoring the array of other factors Perlin
cites as influencing behavior.
While genetics is simply one factor among many affecting behav-
iors, an overemphasis on genetic causes can have unintended conse-
quences.  An individual who learns that she is genetically predisposed
to alcoholism, for example, may try harder to avoid drinking or may
decide that she cannot “fight nature” and succumb to the temptations
of alcohol drinking more than she otherwise would.  As Rothenberg
and Wang point out, by going the latter route she shifts “blame to her
153. Rothenberg & Wang, supra note 145, at 357.  For an expanded discussion of the R
theories underlying punishment and criminal responsibility and their interplay with infor-
mation about genetically based behavior traits, see Rebecca Dresser, Criminal Responsibility
and the “Genetics Defense,” in GENETICS AND CRIMINALITY 163 ( Jeffrey R. Botkin et al. eds.,
1999), and Matthew Jones, Note, Overcoming the Myth of Free Will in Criminal Law: The True
Impact of the Genetic Revolution, 52 DUKE L.J. 1031 (2003).
154. MICHAEL L. PERLIN, THE JURISPRUDENCE OF THE INSANITY DEFENSE 32 (1994); see also
Richard C. Boldt, The Construction of Responsibility in the Criminal Law, 140 U. PA. L. REV.
2245, 2246–47 (1992) (examining the divergence between causal factors that influence
choice and free will).
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genes and away from her individual autonomy,” thus fulfilling the
“prophecy of genetic determinism.”155
4. New Technology
The fourth factor that emerged as pertinent to judicial decision-
making in this area was the comfort level of the individual judge with
this technology and its more recent application to health- and behav-
ior-related tests in court proceedings.  A number of authors have pre-
dicted that judges are likely to embrace health-related genetic tests.
This view touts the seductiveness of such tests, pointing out that “rela-
tive to other kinds of evidence, . . . genetic . . . evidence appears more
precise, constricts the need for interpretation by various experts, and
therefore more quickly and definitively resolves otherwise compli-
cated disputes.  It ‘offers seemingly definitive answers at a time of frus-
tration with the vagueness of other disciplines.’”156  For example,
Halwani and Krupp argue:
Unlike the types of psychological evidence that are rou-
tinely raised in court, reliable genetic evidence poses less evi-
dentiary problems than ‘rotten social background’ evidence
or evidence of mental illness with no recognised biological
basis.  Genes create more certainty: genes don’t lie and may
back up the claims of an accused with solid scientific
evidence.157
Despite the fact that judges in our survey were largely very posi-
tive about the use of DNA testing for identification purposes in crimi-
nal and paternity cases, they did not wholeheartedly embrace this
second generation of genetic tests.  Rather, they were much more dis-
criminating in determining whether the tests should be introduced
into court proceedings.  Where, for example, the tests were to be used
for predictive purposes, the judges seemed skeptical and concerned
about their potential power and persuasiveness.158  In final comments
155. Rothenberg & Wang, supra note 145, at 357. R
156. Denno, supra note 16, at 253 (quoting Dorothy Nelkin, After Daubert: The Relevance R
and Reliability of Genetic Information, 15 CARDOZO L. REV. 2119, 2127 (1994)).
157. Sana Halwani & Daniel Brian Krupp, The Genetic Defence: The Impact of Genetics on the
Concept of Criminal Responsibility, 12 HEALTH L.J. 35, 41 (2004) (footnote omitted); see also
Denno, supra note 16, at 253 (“Because such evidence can give an ‘aura of truth,’ it conse- R
quently provides more power to technical experts and those who can pay for the new
scientific techniques.” (citing NELKIN & TANCREDI, supra note 138)). R
158. But, the potential persuasiveness of the tests may not be the judges’ only concerns.
They may have moral or ethical reasons for caution in applying the technology to predict
behavior or disease.  These reasons may include:
(1) [genetic evidence’s] historical association with past abuses by the Nazis dur-
ing the Holocaust; (2) its potential chilling of our notions of free will; (3) its
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about the survey and about genetic testing generally, one judge said:
“we’re scared of it because it’s a new technology.” Judges, like mem-
bers of the broader society, may not trust new technologies, at least
initially, and fear unknown consequences of their use outside of the
contexts for which they were developed.
V. THE VALUE OF HEALTH-RELATED GENETIC TESTS IN THE
COURTROOM VS. THE “COLLATERAL CONSEQUENCES” OF
THEIR WIDESPREAD USE
While trial court judges rightly must evaluate the benefit of ge-
netic tests in the cases before them, appellate judges, legislators, and
policymakers who promulgate evidentiary and procedural rules and
polices governing litigation should also be concerned about the
broader judicial and public policy implications of using these tests
routinely in court.  Ideally, these rule makers will consider whether
the use of health-related genetic tests will, on the whole, lead to “bet-
ter” or “fairer” and more accurate judicial outcomes and, if they do,
whether such incremental improvements are worth some of the “col-
lateral consequences,” i.e., the social ramifications of a general move-
ment to accept the use of these tests in non-clinical settings.
A. Better Outcomes?
To determine whether the admission of genetic test results in liti-
gation will lead to “fairer” or “more accurate” results, each case must
be evaluated on its own specific facts.  In our hypotheticals, whether
better outcomes would result if the genetic test at issue were admitted
into evidence is not consistently clear.  In the criminal case where the
defendant wanted to admit the results of a genetic test for schizophre-
nia (Hypothetical #1), the test would show only that the defendant
had a 50–60% chance of manifesting the disease at the time of the
crime.  Without the test, the defendant would likely need to rely com-
pletely on the testimony of psychiatrists with expertise in schizophre-
nia diagnosis or upon the testimony of witnesses who observed the
defendant’s behavior or interacted with the defendant at the time of
the crime.  If there were opposing experts, the test results might pro-
vide some valuable additional information to a jury or judge trying to
determine whether the defendant had the disease (and ultimately, the
stigmatizing effect . . . ; and, more recently (4) its potential absolution of societal
responsibility for the social and economic factors that could lead to crime if soci-
ety finds a genetic-defect defence acceptable.
Denno, supra note 16, at 254 (citations omitted). R
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necessary mens rea) at the time, but the information would be proba-
bilistic in nature and could confuse a jury.  If the jury gives the evi-
dence greater or lesser weight than it is due, it could make the process
less accurate.
In the medical malpractice case (Hypothetical #3), the genetic
test result would arguably lead to a fairer resolution.  Without the test
result, the defendant might be ordered to pay for damages he did not
cause.  The toxic tort case (Hypothetical #4), however, is less clear.
Given the complexity of the interaction between genetic susceptibility
and toxic exposure, judges and juries could be confused by the infor-
mation and inaccurately impute greater significance to the test results
than is warranted.  Similarly, we question whether the use of genetic
tests in damage cases (Hypotheticals #5 and #6) will result in “better”
outcomes.159  For the most part, in the context of damage calcula-
tions, these tests will be used for purposes of prognostication.  Their
accuracy for determining life expectancy will depend on the pene-
trance of the gene and the variability of its expression.
B. Implications for Existing Law
The introduction of health-related genetic tests in the courtroom
also has implications for existing law which, when initially conceived,
did not contemplate the likes of this type of technology.  The issues
raised by the introduction of these tests in litigation, highlighted by a
number of hypotheticals in our survey, may lead trial attorneys to
push law and policymakers to reconsider some of our existing legal
doctrines and their underlying polices.  In some cases such reconsid-
eration may be appropriate.  In others, the current legal framework
may adequately accommodate the policy and theoretical tensions un-
derlying the doctrine.  For example, in the criminal context, defense
attorneys may want to use genetic test results as a mitigating factor in
sentencing.  This may challenge the notions of free will undergirding
our common law legal system.160 The use of the tests in criminal cases
159. But see Garrison, supra note 25, at 460 (“Once courts confront the fears of using R
genetic evidence in civil cases, the parties will benefit from more accurate claim adjudica-
tion, whether in calculating lifetime expectancy damages or proving legal causation.”).
160. Whether the criminal justice system will need to change in response to genetic
information that predisposes individuals to behave in certain ways has been the basis of
increasing scholarly discourse and debate. See, e.g., Dresser, supra note 153, at 163 (con- R
cluding that “courts will need guidance on the proper response to claims of a genetics
defense”); Farahany & Coleman, supra note 33, at 116 (“[I]rrespective of the scientific R
progress in the field of behavioral genetics . . . such evidence has little utility in assessing
criminal responsibility.”); Friedland, supra note 111, at 308–09 (warning that a shift from R
“free will to . . . [genetic] determinism . . . would create pressure to reinvent the current
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also, arguably, stretches our Fourth, Fifth, and Fourteenth Amend-
ment jurisprudence to consider the limits of the government’s ability
to intrude into new dimensions of privacy and may force courts to re-
examine the contours of that elusive principle.
In the torts arena, the tests may provoke a rethinking of our tradi-
tional rules governing causation, an area already plagued by difficul-
ties in addressing complex, multifactorial diseases such as cancer.
While genetic tests may initially be perceived as providing more cer-
tainty about the role of genetics in the ultimate disease process when
an injury or medical condition has multiple causes, our ability to dis-
aggregate causes of complex disorders will continue to be based on
epidemiological data, much of which is not available.  As a result, in-
troducing genetic tests into causation decisions may muddy the
analysis.
The use of genetic tests in the damages phase of a trial may also
prod judges to reconsider how much weight we give to life expectancy
in determining damages.  While genetic tests will not allow us to know
exactly how long someone will live, they may allow us to improve our
accuracy in such estimations.  However, even if a genetic test would
allow us to predict with 100% accuracy when someone would die and
to “custom tailor” damage awards based on individual genetic
makeup, we may not be comfortable using someone’s intrinsic and
immutable characteristics against her.  Courts already allow juries to
consider whether a plaintiff has a pre-existing illness, such as cancer
or heart disease, in arriving at a damage award.161  This new technol-
ogy has the ability to accelerate judicial movement along this path: it
pushes the envelope of current tort doctrine as it pertains to damage
calculations highlighting tensions between longstanding goals of accu-
rate compensation, deterrence, and retributive justice.162
Finally, the availability of behavior-related genetic tests for traits
such as aggression or addiction may provoke prosecutors to call for a
reexamination of our rules of evidence and may tempt policymakers
to consider changes in these rules.  Under the current framework es-
tablished by the Federal Rules of Evidence, character evidence is gen-
erally inadmissible to show that a person acted consistently with her
understanding of criminal responsibility”); Johnson, supra note 16, at 470 (suggesting that R
the criminal justice system and the nature of criminal responsibility will change as genetic
technologies advance); Jones, supra note 153, at 1050 (arguing that the current criminal R
law framework can accommodate this new information and need not drastically change).
161. Rothstein, Preventing the Discovery, supra note 24, at 885. R
162. See supra notes 113–114 and accompanying text. R
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character,163 as it may so “overpersuade” juries “about a person’s bad
character that they deny the person a fair hearing.”164  This rule ar-
guably makes sense in the context of the introduction of genetic tests
for behavioral traits.  However, there are a number of exceptions to
the rule.165  Some of these exceptions may be used to the advantage of
the defendant;166 others benefit the prosecution.167  In addition,
there are exceptions that may affect other individuals involved in liti-
gation, e.g., the alleged victim168 or a witness for either side.169
Changing the rules to allow for a more liberal admission of char-
acter evidence would seem, at least in criminal cases, to fly in the face
of the underlying premise of our criminal justice system “that a defen-
dant must be tried for what he did, not who he is.”170  Providing for
more flexibility in the admission of character evidence also animates
consideration of psychological theories of behavior.  These theories
have evolved over the last fifty years from the “trait or generality the-
ory,” popular in the 1950s,171 to the “theory of situationism,” popular
163. See supra note 110. R
164. ROBERT E. JONES ET AL., RUTTER GROUP PRACTICE GUIDE: FEDERAL CIVIL TRIALS &
EVIDENCE ¶ 8:1127 (2006); see also BENNETT L. GERSHMAN, PROSECUTORIAL MISCONDUCT
§ 10:2 (2d ed. 1999) (“The deep tendency of human nature to punish, not because our
victim is guilty this time, but because he is a bad man and may as well be condemned now
that he is caught, is a tendency which cannot fail to operate with any jury, in or out of
court.” (quoting JOHN HENRY WIGMORE, EVIDENCE IN TRIALS AT COMMON LAW § 57 (3d ed.
1940))).
165. For example, character evidence is admissible where character itself is an element
of a crime or claim, e.g., defamation. FED. R. EVID. 405(b).  Such evidence may also be
admissible to rebut the assertion of a character trait by the accused or to establish the
character of an alleged victim or witness. FED. R. EVID. 404(a)(2)–(3) & 607–609.
166. The defendant in a criminal case may offer evidence of his own good character.
FED. R. EVID. 404(a)(1).
167. If the defendant has “opened the door” by bringing in evidence of his own charac-
ter, the prosecution may rebut with character evidence. FED. R. EVID. 404(a)(1).
168. The defendant in a criminal case may attack pertinent traits of the character of the
alleged victim. FED. R. EVID. 404(a)(2).
[I]n a homicide case in which the defendant claims that the alleged victim was
the first aggressor, the defendant would be allowed to call witnesses to testify that
the victim had a violent character.  When the defendant makes this attack, the
prosecution can rebut by supporting the victim’s character or by attacking the
defendant’s character for the same trait.
ROGER C. PARK, TRIAL OBJECTIONS HANDBOOK § 2:7 (2d ed. 2001).
169. Evidence of the character of the witness may be admitted to show or rebut the
witness’s credibility. FED. R. EVID. 404(a)(3).  This includes exploring the mental capacity
of the witness, FED. R. EVID. 607, as well as the witness’s character “for truthfulness or
untruthfulness.” FED. R. EVID. 608.
170. GERSHMAN, supra note 164, § 10:2 (citing United States v. Vizcarra-Martinez, 66 R
F.3d 1006, 1014 (9th Cir. 1995)).
171. Edward J. Imwinkelried, Some Comments About Mr. David Karp’s Remarks on Propensity
Evidence, 70 CHI.-KENT L. REV. 37, 44 (1994).  Imwinkelried writes: “According to this the-
ory, even when there is only a ‘miniscule sample[ ] of [the person’s] prior behavior,’ it is
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in the ’60s and ’70s,172 to the more recent “interactionist theory.”173
In the recent past, some have argued that this evolution “cuts in favor
of liberalizing the character evidence prohibition.”174  We would urge
caution in any movement toward liberalization of evidence rules
based on new genetically based evidence.
C. Broader Implications
In ruling on questions to admit or compel genetic tests for health
conditions and behavioral traits, judges will be making decisions that
are at the intersection of several larger societal, political, and legal
controversies.  Those decisions will have implications that are much
more significant than those resulting from the resolution of the case
at hand.  These controversies include, among other issues, the role of
science in judicial decisionmaking.
In Science at the Bar, Sheila Jasanoff describes the interplay be-
tween law and science as one in which the boundaries, which we often
take for granted as hard and fast, are often negotiated.175  In this ne-
gotiation process, “legal disputes around scientific ‘facts’ often appear
as sites where society is busily constructing its ideas about what consti-
tutes legitimate knowledge . . . and how much deference science
should command in relation to other modes of knowing.”176  Further-
more, she asserts that “science and technology in the legal system inva-
riably redraw the lines of power and authority, as when the law opens
up new areas of technical decisionmaking to review or control by non-
expert publics.”177
To a large extent the trend in the legal system, and society more
broadly, has been to honor science in all its “objective” glory, shroud-
possible to draw a trustworthy inference as to character and then to use that inference as
the basis for a further, reliable inference as to the person’s conduct on a particular occa-
sion.” Id. (alterations in original) (citing Susan M. Davies, Evidence of Character to Prove
Conduct: A Reassessment of Relevancy, 27 CRIM. L. BULL. 504, 513 (1991)).
172. Id. at 44–45 (“Situationist theorists denied that persons possess relatively perma-
nent character traits which are predictive of conduct even in highly similar situations.”).  In
reaction to situationism, “some legal commentators urged that character evidence has ab-
solutely ‘no probative value’ on the question of a person’s conduct on a specific occasion.”
Id. at 45 (citing Robert G. Spector, Commentary: Rule 609—A Last Plea for Its Withdrawal, 32
OKLA. L. REV. 334, 351 (1979)).
173. Id. at 45. According to the interactionist theory, “if there is a sufficient sample of
the person’s behavior in similar situations, the person’s conduct in an analogous situation
can be accurately forecast on the average.” Id. (citing Davies, supra note 171, at 517–20). R
174. Id. at 45 (citing Davies, supra note 171, at 519). R
175. JASANOFF, supra note 11, at xiv–xv. R
176. Id. at xv.
177. Id. at xvi.
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ing it with a protective cloak and giving it heightened deference.178
This has been accomplished in the courtroom by either “delegating
scientific issues to scientists or making legal actors more technically
literate.”179  The latter has included proposals to carve out specialty
science courts in which a cadre of judges, trained in science, would be
the arbiters of science-based disputes.180  Yet, these proposals, as Jasa-
noff argues, “chronically overestimate the power of experts to ration-
alize moral and political choices about science and technology.”181
The more difficult decisions that ultimately must be made in these
disputes are not necessarily the technical ones, but rather are deci-
sions that involve tradeoffs between conflicting values that must be
weighed and titrated.  In the case of genetic tests for health and be-
havioral conditions, those values include scientific accuracy, the need
for a just resolution of a real dispute, the importance of individual
and family privacy, and the protection of family relationships.  In
some cases, the legal system has determined that justice and other
societal values outweigh scientific accuracy.182
Courts have come under attack for their elevation of science and
technology, informed, some argue, by an “unexamined technological
determinism.”183  The criticism, however, has not been one-sided.
Other voices charge that courts have been too cautious in their think-
ing about technology, exaggerating its risks and squelching innova-
tion.184 Consistent with the view of Jasanoff and others, we would
178. Id. at 6 (calling the phenomenon “a manifestation of our society’s deep commit-
ment to a rational, and hence reliably objective, policy process”). See generally, e.g., Edward
P. Richards, The Jurisprudence of Prevention: The Right of Societal Self-Defense Against Dangerous
Individuals, 16 HASTINGS CONST. L.Q. 329, 340 (1989) (“Public health jurisprudence is
based on a deference to scientific decision making.”); Jones, supra note 153, at 1047–48 R
(“[T]he criminal justice system may be more likely to integrate genetics because—unlike
social science—genetics is ‘hard’ science.”); Gary E. Marchant, Pollution, Science and Regula-
tory Decision Making, http://www.law.asu.edu/?id=8300 (last visited May 21, 2007)
(“[G]reater deference [is given] to agency decisions allegedly based on ‘objective’ science
rather than policy, political or economic considerations.  This tendency to cloak policy
judgments under the guise of science is referred to in the legal literature as the ‘science
charade.’”); Austin Dacey, Science and the Public, The Center for Inquiry, http://
www.scienceandthepublic.org/description.htm# (last visited May 21, 2007) (discussing the
center’s research in the area and explaining how “[t]he implicit social contract between
science and other institutions in society makes the issue of the public’s participation in
science policy especially controversial”).
179. JASANOFF, supra note 11, at 6. R
180. Id. at 7.
181. Id.
182. See id. at 10–11 (“[T]he legal system’s allegiance to values other than those of sci-
ence may open the way to decisions that look like sheer irrationality.”).
183. Id. at 12.
184. Id.
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argue that in determining whether to admit or compel health- and
behavior-related genetic tests, judges should base their decisions on a
careful assessment of the multiple factors and values at stake, not a
blind allegiance to the “technological imperative.”
A second controversy highlighted by the introduction of health-
related genetic tests in court proceedings is the role of courts in pro-
tecting personal and family privacy.  These issues are at the heart of
concerns about broad based judicial acceptance of genetic tests that
reveal information about an individual’s current health condition, or
predisposition to certain diseases or behavioral traits.  What may be
most unique about these second generation genetic tests (setting
them apart from DNA tests for identity), however, is that they not only
reveal personal health and behavioral information about a party to a
legal action but they also reveal private and potentially unwanted
health information to the family members of those individuals.  These
“innocent bystanders” may be significantly harmed by this new knowl-
edge.  Its revelation may also have significant ramifications for familial
relationships and may lead to a breakdown in family ties, thus under-
mining a societal and judicial goal of preserving harmonious family
relationships.185
Privacy is a dominant value in our culture, public policy, and ju-
risprudence.  Yet, privacy is not unassailable or incapable of being
trumped by higher values.  In our current political climate, despite
laudable governmental goals to establish protections for personal
health information through extensive government regulations, those
regulations have many exceptions that allow access to such informa-
tion for “higher” public policy reasons, among them law enforce-
ment.186  Moreover, outside the realm of health information, the
185. See Rothenberg, supra note 149, at 118–23 (discussing the concern that genetic
testing will threaten family privacy); see, e.g., Tamar Lewin, In Genetic Testing for Paternity,
Law Often Lags Behind Science, N.Y. TIMES, Mar. 11, 2001, § 1, at 1 (describing a paternity
case in which DNA testing revealed that an alleged father did not carry the cystic fibrosis
mutation and thus could not be the father of three of four children he assumed were his).
186. For example, Congress passed The Health Insurance Portability and Accountability
Act of 1996, Pub. L. No. 104-191, 110 Stat. 1936, and authorized the Department of Health
and Human Services to promulgate regulations governing identifiable health information.
See 45 C.F.R. § 164 (2006) (discussing the disclosure of health information).  Section
164.512 lists specific exceptions to allow disclosure of protected health information to gov-
ernment entities, including information about victims of domestic violence or abuse; infor-
mation needed for health oversight agencies to complete their mission; information
needed for judicial or administrative proceedings; and information necessary for law en-
forcement purposes, which has explicitly defined parameters. See generally Daniel J. Solove,
The Origins and Growth of Information Privacy Law, in 1 6th ANNUAL INSTITUTE ON PRIVACY
LAW: DATA PROTECTION—THE CONVERGENCE OF PRIVACY & SECURITY 23 (2005) (reviewing
the historical and legal precedents for current privacy law).
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broader right to privacy seems under siege, with intrusions from un-
regulated cyberspace and from government efforts to combat
terrorism.187
Despite the societal value of privacy, claims for accountability, a
social good, may outweigh claims to personal privacy.188  Allen argues
that “[a]ccountability imperatives drive the law of tort and crime” and,
absent some type of protective privilege, one cannot simply respond
“[n]one of your business” to demands to explain one’s behavior when
accused of a crime or a negligent act.189  Such reasoning accounts for
breaches of privacy in the courtroom when justice is at stake.  Yet, one
cannot paint with a broad brush and determine that in all cases ac-
countability trumps privacy in the courtroom or, more precisely, that
requests to invade a party’s privacy are in furtherance of a goal of
accountability.  For example, in tort cases where there is likely to be a
request to compel or admit genetic tests, it seems reasonable to distin-
guish between those requests that are in the context of causation and
those that are in the context of a damage calculation.  In cases involv-
ing causation, the use of the information is likely to be consistent with
the goal of accountability, i.e., of determining whether the defendant
caused the plaintiff’s harm and thus should be accountable for his
negligent conduct.  In the context of damages, using private personal
health information against a plaintiff to reduce his award may lead to
a more accurate determination of a plaintiff’s life expectancy.  How-
187. See, e.g., L.A. Chung, Privacy Rights Erode Under Patriot Act, SAN JOSE MERCURY NEWS,
Feb. 22, 2006, available at http://www.keepmedia.com/pubs/MercuryNews/2006/02/22/
1239543 (noting that the PATRIOT Act allows the government to obtain citizens’ personal
information very easily); John Podesta, USA Patriot Act: The Good, the Bad, and the Sunset,
HUM. RTS.: J. OF THE SEC. OF INDIVIDUAL RTS. & RESPS. MAG., 2002, at 3 (“The potential for
abuse, for invasion of privacy, and for profiling citizens is high.”); Another Cave-In on the
Patriot Act, N.Y. TIMES, Feb. 11, 2006, at A14.  Moreover, during the last decade and a half,
the courts have chipped away at the Fourth Amendment requirement of probable cause.
This has occurred both in the context of individualized criminal procedures, e.g., the use
of nontestimonial identification orders used to extract physical evidence from suspects
prior to arrest without a search warrant and outside the criminal process. See supra note 74 R
(describing “special needs” cases).  Notably, rather than resulting in greater protections,
the availability of DNA tests and the collection of DNA evidence for purposes of identity
seem to have been at the heart of these cases.  Much of this jurisprudence has been specifi-
cally in response to DNA testing for the purpose of establishing state and federal DNA data
banks.  These data banks in large part exist to assist in solving future crimes as well as
crimes that have already been committed but were not specifically under investigation
when the sample was obtained.  Miller v. U.S. Parole Comm’n, 259 F. Supp. 2d, 1166, 1176
(D. Kan. 2003).
188. See Anita L. Allen, 2003 Daniel J. Meador Lecture: Privacy Isn’t Everything: Accountability
as a Personal and Social Good, 54 ALA. L. REV. 1375, 1376 (2003) (“[A]lthough privacy is
important, it is not everything.”).
189. Id. at 1376–77.
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ever, it not only undervalues privacy, it also arguably undervalues the
goals of deterrence and fairness across defendants and reduces the
goal of accountability by divorcing damages from proportionality to
fault.
In weighing various factors that are at stake in decisions to admit
or compel genetic tests in the courtroom, judges will be acting in a
current climate that is inhospitable to privacy claims.  This may make
decisions to overlook privacy claims more palatable but will perhaps
make judges more wary about further infringements on an already
weakened societal value.
Wide-scale acceptance of these tests in the courtroom may also
impact how genetic tests are used outside the courtroom.  For exam-
ple, they may hinder the use of genetic tests in the clinical setting or
in medical research, creating a chilling effect on patients’ willingness
to have a genetic test for diagnostic or therapeutic purposes because
of fear of that information coming out in a court proceeding, perhaps
a child custody case.  The infringement on personal privacy when
known medical information is revealed without consent is also a factor
that deserves weight in the decisionmaking matrix.  Currently, when
individuals are told the risks of a genetic test in the clinical setting as
part of an informed consent process, they are not told that the test
result could be used against them in a legal proceeding.  If this risk
were to be disclosed, it could impact individual willingness to obtain
such tests, even for therapeutic purposes.190
There may be other implications as well, depending on the spe-
cific genetic test at issue.  If courts use the test to indicate sensitivity to
pain, for example, it could change our view of pain and suffering such
190. See Seiden & Morin, supra note 146, at 91 (“[I]f patients fear that a blood or tissue R
sample might be used against them in a court of law, they might be reluctant to allow a
physician to perform certain tests or procedures.”).  When genetic tests for medical pur-
poses were first becoming available, use of the information by insurers and employers fu-
eled the fears of patients and potential subjects in genetic research. See, e.g., Diane E.
Hoffmann, The Biotechnology Revolution and its Regulatory Evolution, 38 DRAKE L. REV. 471,
482 (1989) (discussing the concerns about genetic discrimination and invasion of privacy
at the start of the Human Genome Project); Robert Wachbroit, Making the Grade: Testing for
Human Genetic Disorders, 16 HOFSTRA L. REV. 583, 590–91 (1988) (raising privacy and em-
ployment-related issues, among others); Society for Women’s Health Research: Health Pol-
icy: Issues: Genetic Nondiscrimination: Policy Statement, http://www.womenshealth
research.org/site/PageServer?pagename=policy_issues_nondisc_ps (last visited May 21,
2007) (Policy statement on Genetic Nondiscrimination states: “The Society is particularly
concerned about the impact of genetic discrimination on the participation of women in
clinical trials. . . .  [W]omen will be reluctant to enroll in clinical trials if they fear that their
medical information will be used against them by health insurers and employers”); see also
Rothenberg & Terry, supra note 7, at 196 (noting the fear that genetic testing may lead to R
discrimination by insurance companies and employers).
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that we do not rely on patient subjective reporting.  In family law cases
involving adoption or child custody, use of such tests may change our
notions of what it means to be a “good parent,” i.e., is it one who will
not develop a genetic condition with a short life expectancy?  Wide-
spread acceptance of the tests in the courtroom could also change our
expectations of when it is appropriate to be tested.  For example, we
may come to expect that everyone have a genetic test before marriage
or prior to conceiving a child.
VI. CONCLUSION
The value of genetic test results for purposes of providing infor-
mation about the health status of one of the parties in a court pro-
ceeding will depend, in large part, on its admission into evidence.  In
our adversary system, judges are assigned the role of gatekeepers in
admitting or keeping out information for consideration by the trier of
fact.  In the case of health- and behavior-related genetic tests, judges
will initially be required to determine whether the test in question
meets the relevant Daubert or Frye test in that jurisdiction.  However,
once that threshold test is met, judges will still have discretion to de-
termine the probative value of the information and whether that value
is outweighed by “risks” of the information, including its potential to
mislead or confuse the jury.
While compelling or admitting genetic tests in some court pro-
ceedings may be beneficial, judges will need to take a fine-tuned, case-
by-case approach in deciding how to respond to these requests.  More-
over, appellate court judges and policymakers who determine proce-
dural rules governing litigation will need to consider the collateral
consequences of wide-scale use of the tests in the courtroom.  The use
of these tests will not only have far-reaching implications for the out-
come of court cases and the shape of future legal doctrine, but also
may affect how we, as a society, think about responsibility, privacy, and
justice.
